| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
ADMA Biologics Inc$9.08
-0.08 (-0.86%)
D 36Pipeline Score Richly Valued Biotech · Commercial
Market Cap
1.76 B
EPS
0.69
P/E Ratio
11.21 $
Value Trade
22.46 M
SEC Financials
Q1 2026Dilution Risk
Revenue
114.49 M
R&D Expenses
2.60 M
Operating CF
58.25 M
Total Assets
665.18 M
Total Liabilities
274.86 M
Equity
390.32 M
D/E Ratio
12,345
-2.83 %
Week
-23.92 %
1 Month
-49.1 %
3 Month
-49.63 %
6 Month
362.92 %
5 Year
17.71 %
All Time
Cash Data
Cash Position
138.15 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
2.34 M
52 Week Range
7.21 - 22.37
% held by Insiders
2.83 %
% held by Institutions
91.95 %
Enterprise Value
1.83 B
Total Shares
231.70 M
Short %
10.73 %
Float Shares
225.91 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for ADMA Biologics Inc
514Total events
2Upcoming
151Tier-1 (high impact)
2013 – 2030Coverage
Upcoming catalysts 2
Event history 512
May 6, 2026
May 4, 2026
▲Label ExpansionASCENIVApprovedFDA Decision
FDA approval to expand ASCENIV label to include pediatric patients 2 years and older
primary humoral immunodeficiency (PI)source ↗
May 2026
◆Oral PresentationASCENIVApprovedPresentation
Positive, statistically significant real-world ASCENIV outcomes to be presented at CIS in May 2026
primary humoral immunodeficiencysource ↗
Apr 2026
▲Quarterly UpdateASCENIVApprovedCorporate
April 2026 demand run-rate in-line with Q1 2026 direct sales
primary humoral immunodeficiencysource ↗
Q1 2026
▲Quarterly UpdateASCENIVApprovedCorporate
ASCENIV revenue $97.5M in Q1 2026, 28% YoY growth
primary humoral immunodeficiencysource ↗
Q1 2026
▼Quarterly UpdateBIVIGAMApprovedCorporate
BIVIGAM revenue $15.4M in Q1 2026, -54% YoY decline
primary humoral immunodeficiencysource ↗
Mar 24, 2026
▼Short Report ActivistCorporate
Culper Research published short report alleging channel stuffing and undisclosed related party distributor
Mar 2, 2026
▼Equity OfferingCorporate
ADMA announces $125 million accelerated share repurchase with JPMorgan as part of $200 million 2026 total share repurchase initiative
Feb 25, 2026
Jan 12, 2026
Drug Pipeline Intelligence
D36
Pipeline Score $142M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 50%
Micro Cap (rank 456 of 911)
Percentile RankADMA Biologics Inc faces pipeline headwinds (36/100), with $712M risk-adjusted pipeline value, led by RI-002 in Primary Immune Deficiency Disorder (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RI-002 Monoclonal antibody | Primary Immune Deficiency Disorder | Phase 3 | NCT01814800 | 57% | $564M | COMPLETED | 59 | - | - | Jan 1, 2015 | - | Oct 5, 2016 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ASCENIV Fast Track | Respiratory Syncytial Virus infection | — | 2019-10-07 | Patient one was discharged from the hospital on hospital day eighty-eight, and currently requires no respiratory support.; Patient two was discharged from the hospital on hospital day six. Read More | ADMA Biologics Announces Data Presented at IDWeek 2019 RAMSEY, N.J. and BOCA RATON, FL. Read More | |
ASCENIV Fast Track | Respiratory Syncytial Virus infection | — | 2019-10-07 | Patient one was discharged from the hospital on hospital day eighty-eight, and currently requires no respiratory support.; Patient two was discharged from the hospital on hospital day six. Read More | ADMA Biologics Announces Data Presented at IDWeek 2019 RAMSEY, N.J. and BOCA RATON, FL. Read More | |
ASCENIV Fast Track | Respiratory Syncytial Virus infection | — | 2019-10-07 | Patient one was discharged from the hospital on hospital day eighty-eight, and currently requires no respiratory support.; Patient two was discharged from the hospital on hospital day six. Read More | ADMA Biologics Announces Data Presented at IDWeek 2019 RAMSEY, N.J. and BOCA RATON, FL. Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ADMA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ADMA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ADMAADMA INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ADMA Biologics, Inc. is reportedly facing a class action lawsuit from investors who experienced substantial losses between August 2024 and March 2026. The lawsuit alleges violations of the Securities Exchange Act, specifically citing misleading financial statements, undisclosed related party transactions, and channel stuffing practices. These allegations follow a negative report from Culper Research, which highlighted artificial inflation of reported revenues. The company's stock has seen considerable declines as a result of the unfolding situation.
Read more →ADMAADMA Shareholder Alert: August 10, 2026 Lead Plaintiff Deadline in ADMA Biologics, Inc. Securities Class Action - Contact The Gross Law Firm
ADMA Biologics, Inc. is currently facing a securities class action with allegations of misleading statements and poor internal controls during the class period from August 9, 2024 to March 25, 2026. Shareholders are being alerted to register for potential lead plaintiff roles. The deadline for registration is August 10, 2026. The Gross Law Firm is representing the shareholders and aims to protect their rights against alleged fraudulent practices by ADMA Biologics.
Read more →ADMAADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ADMA Biologics, Inc. is currently facing a class action lawsuit initiated by the Schall Law Firm, citing violations of securities regulations. Investors who acquired shares during the defined class period from August 9, 2024, to March 25, 2026, are encouraged to join the lawsuit due to alleged false and misleading public statements from the company. The accusations include undisclosed related party transactions and internal control failures, leading to damages for investors once the truth was revealed. The class action has yet to be certified, and affected shareholders are urged to take action before the deadline.
Read more →ADMAADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA
ADMA Biologics, Inc. is under legal scrutiny due to a securities class action lawsuit filed in the United States District Court for New Jersey. The lawsuit alleges that ADMA and its executives failed to disclose material information and engaged in potentially misleading practices during the class period from August 9, 2024, to March 25, 2026. A lead plaintiff deadline has been set for August 10, 2026, for investors who suffered losses exceeding $100,000. Investors are encouraged to submit claims and review their legal options.
Read more →ADMAADMA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against ADMA Biologics, Inc. by Bragar Eagel & Squire in New Jersey, representing individuals who acquired ADMA securities between August 9, 2024, and March 25, 2026. The lawsuit claims that the company made misleading statements and failed to disclose significant risks regarding its operations, including allegations of using channel stuffing to inflate revenues. Following a critical report by Culper Research, ADMA's stock experienced a significant decline. Investors interested in joining the lawsuit have until August 10, 2026, to apply as lead plaintiff.
Read more →ADMA$ADMA Fraud Notice: ADMA Biologics Accused of Securities Fraud over Channel Stuffing Allegations in Filed Class Action Lawsuit – Investors Notified to Contact BFA Law
ADMA Biologics is under legal scrutiny as a class action lawsuit has been filed against the company and its executives for securities fraud. The allegations suggest that ADMA engaged in a channel stuffing scheme to inflate its revenue growth, leading to a significant stock drop. Following the lawsuit announcement, ADMA's stock price fell sharply, raising concerns among investors about the integrity of the reported growth figures. The case is currently pending in the U.S. District Court for New Jersey, with a lead plaintiff deadline set for August 10, 2026.
Read more →ADMAADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
ADMA Biologics, Inc. is currently involved in a class action lawsuit initiated by Kahn Swick & Foti, LLC, covering securities bought between August 9, 2024, and March 25, 2026. The lawsuit alleges that the company and its executives did not disclose crucial information, which includes using deceptive practices such as channel stuffing and lacking adequate internal controls. Investors have until August 10, 2026, to request to be appointed as lead plaintiff in this case. The allegations suggest that misrepresentation of the company's operations led to financial losses for shareholders.
Read more →ADMAADMA Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ADMA Biologics, Inc. Class Action Lawsuit
A class action lawsuit has been filed against ADMA Biologics, Inc. on behalf of investors who purchased shares between August 9, 2024, and March 25, 2026. The allegations suggest that ADMA engaged in misleading practices, including undisclosed related party transactions and channel stuffing, contributing to a materially false impression of its business operations. Following the release of a critical report by Culper Research, ADMA's stock price fell by a significant percentage, prompting the action. Shareholders are invited to participate as lead plaintiffs in the ongoing litigation.
Read more →ADMAADMA Shareholder News: ADMA Biologics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law about the Ongoing Securities Class Action
ADMA Biologics is currently involved in a class action lawsuit for securities fraud, following a substantial decline in its stock prices. Allegations suggest that the company misrepresented its financial health by engaging in channel stuffing to enhance revenue figures, claiming a 20% growth for 2025 when a 3% decline was more accurate. The firm's stock experienced drastic losses, dropping 16.6% within one day of negative reports, with further declines following subsequent downgrades by analysts. Investors are being encouraged to seek legal options to recover their losses.
Read more →ADMAADMA Shareholder Alert: ADMA BIOLOGICS, INC. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
ADMA Biologics, Inc. is facing a securities class action lawsuit after allegations claimed that its reported revenue growth was misleadingly inflated through channel stuffing. The lawsuit names key executives including CEO Adam S. Grossman and former CFO Brad Tade, who are accused of signing misleading SEC filings during the class period from August 2024 to March 2026. Investigations suggest that actual revenues may have declined, contradicting the company's positive reports. The court has set a date for potential lead plaintiff appointments, allowing affected investors to seek recovery for their losses.
Read more →ADMAADMA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Faruqi & Faruqi, LLP has announced an impending deadline for ADMA Biologics investors to participate in a securities class action lawsuit. The complaint alleges that the company and its executives did not disclose key information about financial practices, including engaging in undisclosed related-party transactions and channel stuffing. Following a report revealing these practices, ADMA Biologics' stock price experienced a significant decline. Investors who purchased stock between August 9, 2024, and March 25, 2026, are encouraged to review their options before the August 10, 2026, deadline.
Read more →ADMA$ADMA Class Action Alert: ADMA Biologics Channel Stuffing Claims and 16% Stock Drop Leads to Securities Fraud Class Action – Contact BFA Law to Protect Your Rights
ADMA Biologics, Inc. is facing a class action lawsuit by securities law firm Bleichmar Fonti & Auld LLP for alleged securities fraud. The lawsuit follows a significant stock drop of 16.6% on March 24, 2026, attributed to claims that the company engaged in channel stuffing to artificially inflate reported revenue growth. A report by Culper Research indicated that had ADMA not allegedly participated in this scheme, it would have experienced a 3% decline in revenue instead of the reported 20% growth for the year. The lawsuit underscores concerns about financial integrity and transparency within the company, prompting investors to seek legal counsel.
Read more →ADMAADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
ADMA Biologics, Inc. has been sued for securities fraud by Block & Leviton, alleging that the company misled investors regarding its revenue growth from ASCENIV. The complaint claims that ADMA engaged in a channel-stuffing scheme and failed to disclose a related-party distribution relationship with Genesis BioPharma Services. Following a report by Culper Research revealing these issues, ADMA's stock price fell dramatically. Investors affected by these developments are encouraged to contact the law firm for potential recovery options.
Read more →ADMAADMA INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of ADMA Biologics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm
A shareholder class action lawsuit has been initiated against ADMA Biologics, Inc. The complaint contends that the company made false representations regarding its business, operations, and financial prospects. Specific allegations include undisclosed related party transactions and the use of channel stuffing to modify revenue recognition. Additionally, the lawsuit highlights deficiencies in the company's internal controls. Investors who purchased shares during a specific period and incurred losses are encouraged to reach out to Holzer & Holzer, LLC for legal assistance.
Read more →ADMAADMA Biologics Investigation: ADMA Biologics (ADMA) Investigated for Alleged Channel Stuffing – Contact BFA Law if You Suffered Losses
ADMA Biologics, Inc. is currently under investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws. The investigation centers around allegations that the company's reported 20% revenue growth in 2025 resulted from a channel stuffing scheme, misleading investors about actual demand. A report from Culper Research claims that without such practices, the company would have experienced a 3% decline in revenue. Following these revelations, the stock price of ADMA Biologics fell sharply by 29%. Investors are encouraged to seek legal options for potential losses.
Read more →ADMAADMA Legal Claims: ADMA Biologics may have Misrepresented its Revenue Sources to Investors – Contact BFA Law about its Pending Securities Fraud Investigation
ADMA Biologics is under investigation by Bleichmar Fonti & Auld LLP for potential securities fraud related to misrepresentation of revenue sources. Allegations suggest that the company's reported 20% revenue growth for 2025 was achieved through a channel stuffing scheme, which masked actual declining demand. Following the release of a critical report by Culper Research, ADMA's stock dropped 29%, highlighting investor concerns over the accuracy of its financial reporting and growth figures.
Read more →ADMAADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims on behalf of ADMA Biologics shareholders due to allegations of the company issuing misleading business information. This follows a report by Culper Research accusing ADMA of channel stuffing to inflate revenue growth, leading to a substantial drop of 16.6% in stock value. Investors impacted by these allegations are encouraged to join a class action lawsuit to seek compensation for their losses. The firm emphasizes the importance of selecting experienced legal counsel for such cases.
Read more →ADMA$ADMA Securities News: ADMA Biologics Investigated for Securities Fraud Over Channel Stuffing Allegations – Investors with Losses Notified to Contact BFA Law
ADMA Biologics, Inc. is under investigation for alleged securities fraud involving a channel stuffing scheme to inflate revenue figures. Reports indicate that the company misrepresented a 20% revenue growth in 2025, which was allegedly driven by improper practices to boost sales figures artificially. The allegations surfaced after a report from Culper Research revealed that the actual growth may have been a decline of 3%. Following the news, ADMA's stock price fell sharply by 29%.
Read more →ADMAADMA Investor Alert: Did ADMA Biologics Mislead Investors about Alleged Channel Stuffing? BFA Law Notifies Investors with Losses of the Pending Securities Fraud Investigation
Bleichmar Fonti & Auld LLP is investigating ADMA Biologics, Inc. for potential securities fraud violations related to misleading revenue reporting. Allegations indicate that ADMA's reported 20% revenue growth in 2025 may have been artificially created through channel stuffing practices. Following the release of a critical report by Culper Research, ADMA's shares plummeted by 29%. Investors are encouraged to explore their legal options as the investigation unfolds.
Read more →ADMA$ADMA Shareholder Announcement: ADMA Biologics may have Misled Investors about its Revenue – Contact BFA Law about its Pending Investigation
ADMA Biologics, Inc. is facing an investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws. The inquiry follows allegations that the company engaged in channel stuffing to inflate its reported revenue growth for 2025. Research by Culper Research indicated that ADMA's actual growth was only a -3% decline rather than the 20% growth reported, leading to a significant drop in its stock price after the disclosures. Investors in ADMA Biologics are encouraged to seek legal counsel regarding their options.
Read more →ADMAADMA Inquiry News: ADMA Biologics Investors are Notified of BFA Law’s Ongoing Investigation into the Company’s Potential Misstatements – Contact the Firm if You Lost Money
ADMA Biologics is facing scrutiny from Bleichmar Fonti & Auld LLP over allegations of securities fraud, specifically related to inflating revenue figures through questionable practices, such as channel stuffing. A recent report by Culper Research suggests that the company's claimed 20% revenue growth for 2025 was misleading, indicating a potential revenue decline instead. The investigation has led to a significant decline in ADMA's stock price, falling 29% after the report was published. Investors who may have incurred losses are encouraged to seek further information on legal options.
Read more →ADMAADMA Securities Investigation: ADMA Biologics 29% Stock Drop Triggers Securities Fraud Investigation Over Channel Stuffing Claims – Investors Urged to Contact BFA Law
ADMA Biologics, Inc. is facing a securities fraud investigation by Bleichmar Fonti & Auld LLP due to allegations of channel stuffing. A report by Culper Research claims that the company's reported 20% revenue growth in 2025 was artificially inflated through incentivizing a distributor to hold excess inventory. Following the allegations, ADMA's stock price fell 29%, prompting concerns among investors. This investigation may lead to further legal challenges for the company and its shareholders.
Read more →ADMAADMA Fraud Notice: ADMA Biologics is being Investigated for Securities Fraud after 29% Stock Drop -- Investors Reminded to Contact BFA Law
ADMA Biologics is currently facing an investigation by Bleichmar Fonti & Auld LLP for possible violations of federal securities laws. The inquiry stems from allegations that the company's reported revenue growth in 2025 was artificially inflated through a channel stuffing scheme. This revelation led to a significant decline in the company's stock price, dropping 29% over two trading days. Investors are being encouraged to seek legal guidance regarding their potential claims.
Read more →ADMAADMA Shareholder News: ADMA Biologics Investigated for Securities Fraud Over Alleged Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law
ADMA Biologics, Inc. is currently being investigated by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws concerning allegations of channel stuffing. A report by Culper Research claims that ADMA's reported 20% revenue growth in 2025 may have been artificially inflated, resulting from undisclosed practices intended to mask declining demand. This controversy led to a significant drop in the company's stock price, falling by 29% in just two trading days. Shareholders are being encouraged to seek legal advice regarding this matter.
Read more →ADMAADMA Biologics Inquiry Alert: Investors with Losses After Channel Stuffing Allegations Are Urged to Contact BFA Law About Its Securities Investigation
ADMA Biologics is under investigation by Bleichmar Fonti & Auld LLP for potential securities law violations related to allegations of channel stuffing to misrepresent revenue. A recent report from Culper Research claims that ADMA's reported 20% revenue growth in 2025 was misleading, suggesting that the company induced distributors to inflate sales figures. This controversy has led to a significant drop in ADMA's stock price, decreasing by 29% following the revelations. Investors are advised to consider their legal options due to the implications of these allegations.
Read more →ADMA$ADMA Investigation Reminder: ADMA Biologics Investigation on behalf of Investors is Ongoing – Contact BFA Law if You Lost Money
Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws. This follows a report by Culper Research indicating that ADMA may have engaged in channel stuffing to inflate its 2025 revenue figures. The investigation is prompted by claims that ADMA's reported revenue growth was misleading and could have shown a decline instead. As a result of these allegations, ADMA's stock experienced a significant drop of 29% over two trading days.
Read more →ADMA$ADMA Investor News: ADMA Biologics Stock Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation – Contact BFA Law if You Suffered Losses
ADMA Biologics is facing a securities fraud investigation following claims of channel stuffing that allegedly inflated reported revenues. An investigative report revealed that ADMA's revenue growth for 2025 may have been artificially inflated by inducing a distributor to stock excess products. As a result, the company's stock price fell 29% in two days. The situation has prompted legal options for affected investors through Bleichmar Fonti & Auld LLP.
Read more →ADMA▼ -16%on this newsshared move
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
ADMA Biologics reported its first quarter 2026 financial results, revealing total revenue of $114.5 million, which remained flat year-over-year. ASCENIV revenue saw a 28% increase, while BIVIGAM experienced a significant decline. The company expressed confidence in ASCENIV's growth outlook despite competitive pressures affecting overall market dynamics. Adjusted Net Income and EBITDA both showed substantial year-over-year growth.
Read more →ADMA$ADMA Shareholder News: ADMA Biologics 29% Stock Drop Leads to Securities Fraud Investigation – BFA Law Encourages Investors with Losses to Act
ADMA Biologics is facing a securities fraud investigation following a significant drop in its stock price. The law firm Bleichmar Fonti & Auld LLP announced the investigation over allegations that the company's reported revenue growth in 2025 was artificially inflated through a channel stuffing scheme. According to an investigative report, the company misled investors, resulting in a 29% stock price decline within two trading days. Investors in ADMA are encouraged to explore legal options for potential compensation.
Read more →ADMA$ADMA Stock Drop Alert: ADMA Biologics Stock Plummeted 29% on News of Channel Stuffing – Investors Notified to Contact BFA Law about its Investigation
ADMA Biologics is facing an investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws stemming from allegations of channel stuffing. A report by Culper Research claims that the company misrepresented a 20% revenue growth in 2025, which was allegedly achieved through techniques like incentivizing distributors to stock excess product. As a result of the negative news, the company's stock price plummeted 29% over two trading days. Investors are being notified of potential legal actions as a consequence of these findings.
Read more →ADMAADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older
ADMA Biologics has received FDA approval to expand the label for ASCENIV to include pediatric patients aged two years and older with primary humoral immunodeficiency. This approval allows for earlier treatment of younger patients and reflects the successful completion of required clinical trials. The company aims to enhance the utilization of ASCENIV as a treatment option for immune compromised children.
Read more →ADMAADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Rosen Law Firm has initiated an investigation into ADMA Biologics, Inc. regarding the possibility of misleading information being provided to investors. This follows a significant stock price decline of 16.6% attributed to a report from short seller Culper Research claiming the company engaged in questionable revenue practices. The law firm is preparing a class action to recover losses for shareholders who purchased ADMA Biologics securities. Concerned investors are encouraged to reach out for participation in the legal action.
Read more →ADMAADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
ADMA Biologics, Inc. announced it will report its first quarter 2026 financial results on May 6, 2026. The company will host a live conference call at 4:30 p.m. ET to discuss these results and provide updates. ADMA specializes in manufacturing and marketing specialty biologics for immunodeficient patients.
Read more →ADMA$ADMA Fraud: ADMA Biologics Channel Stuffing Claims Trigger Securities Investigation – Investors Alerted to Contact BFA Law
ADMA Biologics, Inc. is currently facing a securities investigation led by Bleichmar Fonti & Auld LLP due to allegations of channel stuffing that allegedly inflated the company's reported revenue growth of 20% in 2025. According to a report from Culper Research, the actual growth could have been a decline of 3% had the company not engaged in these practices. As a result, ADMA's stock price fell by 29% shortly after the report was published, reflecting investor concerns over the legitimacy of its financial disclosures.
Read more →ADMAADMA Stock: ADMA Biologics Securities Fraud Investigation is Ongoing – Investors with Losses Urged to Contact BFA Law
ADMA Biologics, Inc. is facing an investigation from Bleichmar Fonti & Auld LLP for potential violations of federal securities laws related to allegations of securities fraud. Reports suggest that the company's reported 20% revenue growth for 2025 was artificially enhanced through a channel stuffing scheme. Following the negative news, ADMA Biologics' shares saw a significant drop of 29% over two trading days. Investors are encouraged to seek legal advice regarding the situation.
Read more →ADMAADMA Legal Notification: ADMA Biologics Securities Class Action Investigation Ongoing – Investors with Losses after 29% Stock Drop Notified to Contact BFA Law
ADMA Biologics, Inc. is under investigation by Bleichmar Fonti & Auld LLP for potentially inflating its revenue through a channel stuffing scheme. Following an unfavorable report from Culper Research, ADMA's stock plummeted by 29% in two days, raising concerns about the integrity of its financial reports. Investors who experienced losses due to this stock decline are encouraged to seek legal representation. The investigation highlights serious allegations that could have significant implications for ADMA Biologics and its shareholders.
Read more →ADMA$ADMA Investigation: BFA Law Notifies ADMA Biologics Investors that Lost Money after 29% Stock Drop of Ongoing Securities Fraud Investigation
ADMA Biologics, Inc. is facing an investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws. Allegations suggest the company may have engaged in a channel stuffing scheme to inflate reported revenue for 2025, which misled investors. Following the revelation of these claims by Culper Research, ADMA's stock experienced a 29% decline over two trading days. Shareholders impacted by the drop are encouraged to explore legal options against the company.
Read more →ADMAADMA Securities News: ADMA Biologics Hit with Securities Fraud Investigation after Channel Stuffing Claims Trigger 29% Stock Drop – Investors Urged to Contact BFA Law
ADMA Biologics is currently facing a securities fraud investigation led by Bleichmar Fonti & Auld LLP due to allegations of channel stuffing to misrepresent revenue growth. A recent report from Culper Research questioned the legitimacy of the company's reported 20% revenue increase in 2025, suggesting it was instead a 3% decline. As a result, ADMA's shares dropped significantly, losing 29% of their value in just two trading days. Investors are encouraged to seek legal advice regarding potential claims against the company.
Read more →ADMAADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
ADMA Biologics is currently being investigated by Lowey Dannenberg P.C. for possible breaches of federal securities laws. The investigation follows a report by Culper Research, which accused ADMA of channel stuffing practices to inflate revenue figures inaccurately. Specifically, the report claims the company's inducement of a distributor to stockpile excess ASCENIV led to misleading financial statements, potentially showing a growth that was not genuinely realized. The law firm is looking into whether ADMA provided its investors with truthful and complete information regarding its financial status.
Read more →ADMAADMA Investor Alert: ADMA Biologics Securities Fraud Investigation - Investors With Losses May Seek to Lead the Potential Class Action After Claims Company Overstated Financial Metrics: Levi & Korsinsky
ADMA Biologics is currently the subject of a securities fraud investigation following allegations from a short-seller report that the company overstated its 2025 revenue growth. While ADMA reported a 20% increase, the short-seller claims actual revenue reflects a 3% decline, leading to a sharp drop in ADMA's stock price. Shareholders who experienced financial losses are encouraged to consider joining a potential class action against the company. The investigation raises questions about the accuracy of ADMA's financial disclosures and commercial practices.
Read more →ADMA$ADMA Legal News: ADMA Biologics Investors may have been Affected by Fraud after Channel Stuffing Claims Disclosed – Contact BFA Law if You Lost Money
ADMA Biologics is under investigation by Bleichmar Fonti & Auld LLP for potential federal securities law violations related to alleged channel stuffing to artificial growth in reported revenues. A report by Culper Research claims that the company induced a distributor to stock excess products, inflating revenue figures. Following these claims, ADMA's stock experienced a significant decline of 29% over two trading days. Investors who feel impacted by these developments are encouraged to seek legal advice and possibly join a class action lawsuit.
Read more →ADMA▲ +7%on this newsshared move
$ADMA Investigation Reminder: ADMA Biologics Investors are Reminded to Contact BFA Law after Company Investigated for Securities Fraud Over Channel Stuffing Claims
ADMA Biologics, Inc. is facing an investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws related to alleged channel stuffing practices. Reports indicate that the company's claimed 20% revenue growth in 2025 may have been artificially inflated, masking a potential revenue decline. This led to a significant drop in the company's stock price, falling by 29% within two days. Investors are being urged to consider their legal options in light of these findings.
Read more →ADMAADMA Securities Alert: ADMA Biologics Securities Fraud Investigation Focuses on Channel Stuffing Claims; BFA Law Notifies Investors to Contact the Firm
ADMA Biologics, Inc. is under investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws. Allegations suggest that the company may have engaged in channel stuffing practices to falsely report revenue growth for 2025. A recent report indicated that if these practices had not occurred, the company could have faced a 3% revenue decline instead of the claimed 20% growth. Following the news of the investigation, ADMA's stock experienced a significant decline.
Read more →ADMA▲ +6.2%on this newsshared move
ADMA Investor Announcement: ADMA Biologics Investigated After Channel Stuffing Claims Cause 29% Stock Drop – Investors with Losses Notified to Contact BFA Law
ADMA Biologics, Inc. is currently facing an investigation by Bleichmar Fonti & Auld LLP for potential securities law violations. The scrutiny arises from allegations that the company's reported 20% revenue growth in 2025 was a result of a channel stuffing scheme. Following the publication of a critical report by Culper Research, which challenged the veracity of the company's financial claims, ADMA's stock price experienced a significant decline of 29%. Investors are being urged to explore their legal options in light of these developments.
Read more →ADMAADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
ADMA Biologics, Inc. has seen its stock price plummet by over 16% amid troubling allegations from short seller Culper Research regarding potential financial misconduct. The report claims that ADMA may have engaged in channel stuffing by inducing distributors to stock excess products and extending payment terms, consequently inflating reported revenues. Hagens Berman, a national shareholders rights firm, is now investigating these claims and any possible violations of federal securities laws. The scrutiny comes alongside a harsh downgrade from an analyst who changed the stock's rating from overweight to neutral.
Read more →ADMA$ADMA Stock News: ADMA Biologics Investigated for Securities Fraud Following Channel Stuffing Claims – Investors Notified to Contact BFA Law
ADMA Biologics, Inc. is currently being investigated by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws. This inquiry follows claims that the company's reported 20% revenue growth in 2025 was artificially inflated through a channel stuffing scheme. A recent report by Culper Research alleged that ADMA Biologics incentivized a distributor to overstock its product, resulting in misleading financial reporting. The fallout from these allegations has led to a sharp decline in ADMA's stock price, down 29% over two trading days.
Read more →ADMA$ADMA Securities Alert: ADMA Biologics Investigated for Securities Fraud over Culper Research Report Revelation – Investors with Losses Urged to Contact BFA Law
ADMA Biologics, Inc. is facing an investigation for possible violations of federal securities laws related to allegations of channel stuffing. Culper Research has accused the company of artificially inflating its reported revenue growth for 2025, suggesting that actual growth was only -3% instead of the reported 20%. Following the release of this report, ADMA's stock price plummeted by 29%, raising concerns among investors about potential losses. Legal firm Bleichmar Fonti & Auld LLP is urging affected investors to seek compensation.
Read more →ADMA$ADMA Investor News: ADMA Biologics Faces Securities Fraud Investigation after Culper Research Revelation Leads to 29% Stock Drop – BFA Law Notifies Investors to Act
ADMA Biologics is facing a securities fraud investigation led by Bleichmar Fonti & Auld LLP following a report from Culper Research. The report alleges that ADMA engaged in a channel stuffing scheme to artificially inflate its revenue, misrepresenting a 20% growth in 2025, amid claims of a 3% decline if honest accounting practices were followed. As a consequence of these revelations, ADMA's stock plummeted by 29% within two trading days. Investors who are affected are being encouraged to seek legal advice to explore their options.
Read more →ADMA▲ +11.6%on this newsshared move
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
ADMA Biologics has issued a statement refuting allegations made by short seller Culper Research regarding its product ASCENIV. The company asserts that demand for ASCENIV is increasing and that its inventory levels are consistent with industry standards. ADMA also emphasizes that the allegations reflect a misunderstanding of its business model and the IVIG market dynamics.
Read more →ADMA▲ +11.6%on this newsshared move
ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating ADMA Biologics, Inc. for potential violations of federal securities laws on behalf of its stockholders. The investigation was prompted by a report from Culper Research, which claims that ADMA's reported growth may be misleading due to illicit business practices. After the report's release, ADMA's stock experienced a notable decline, falling by over 16%. The law firm urges affected investors to reach out regarding their legal options.
Read more →ADMA▲ +11.6%on this newsshared move
$ADMA Shareholders: ADMA Biologics Hit with Securities Fraud Investigation After Stock Slides 29% Amid Channel Stuffing Claims – Investors with Losses Alerted to Contact BFA Law
ADMA Biologics, Inc. is under investigation by Bleichmar Fonti & Auld LLP for potential securities fraud. This follows a report from Culper Research alleging that the company's reported 20% revenue growth in 2025 was inflated through a channel stuffing scheme aimed at obscuring declining demand. Consequently, ADMA's stock plummeted by 29% over two days, raising concerns among shareholders about legal recourse for their losses.
Read more →ADMA▼ -15%on this news· ran to -27% by day 1shared move
ADMA Biologics Addresses Misleading Short-Seller Report
ADMA Biologics has responded to a misleading report from Culper Research, which holds a short position in the company. The report is criticized for being based on unreliable sources and containing false statements. ADMA reaffirms its commitment to transparency and compliance with financial reporting standards. The company continues to focus on developing specialty biologics for immunodeficient patients.
Read more →ADMA▲ +6.5%on this news
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
ADMA Biologics has announced a $125 million accelerated share repurchase agreement with JPMorgan as part of a broader $200 million capital return initiative planned for 2026. This move reflects the company's strong financial health and confidence in its growth trajectory. ADMA aims to enhance shareholder value while continuing to invest in strategic growth initiatives.
Read more →ADMAADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ADMA Biologics reported record financial results for FY 2025, with total revenue reaching $510 million, a 20% increase from the previous year. The company highlighted strong growth in ASCENIV sales, which rose by 51%. Despite a decrease in GAAP net income attributed to a prior year's tax benefit, adjusted net income and EBITDA showed significant growth. ADMA is optimistic about future revenue growth and operational improvements.
Read more →ADMAADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
ADMA Biologics, Inc. will announce its fourth quarter and full year 2025 financial results on February 25, 2026. The company will host a live conference call at 4:30 p.m. ET to discuss these results and provide additional updates. ADMA specializes in developing biologics for immunodeficient patients and has several FDA-approved products.
Read more →ADMAADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update FY 2025 Preliminary Unaudited Total Revenue of Approximately $510-511 Million Meets or Exceeds Prior Guidance Previ
ADMA Biologics has announced preliminary unaudited total revenue for FY 2025 of approximately $510-511 million, which meets or exceeds previous guidance. The company reported an estimated operating cash flow of around $40 million for Q4 2025 and had cash holdings of approximately $88 million at year-end. Looking ahead, ADMA anticipates the first full year of yield-enhanced production in 2026, and the rollout of ASCENIV data is expected to further bolster growth. ADMA also reiterated its financial targets for FY 2026 and FY 2027, projecting substantial increase in revenue and adjusted EBITDA.
Read more →ADMAADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
ADMA Biologics announced that CEO Adam Grossman will present at the J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will highlight the company's efforts in developing specialty biologics for immunodeficient patients. A live audio webcast will be available for interested investors.
Read more →ADMA▼ -8.7%on this news
ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update
ADMA Biologics reported strong financial results for Q3 2025, with total revenue increasing by 12% year-over-year to $134.2 million. The company anticipates margin expansion due to the FDA's release of yield-enhanced production batches. ASCENIV demand remains robust, supported by positive health outcomes and expected payer coverage expansion. ADMA has raised its revenue guidance for FY 2025 and 2026, projecting significant growth in the coming years.
Read more →ADMAADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025
ADMA Biologics, Inc. has announced that it will report its third quarter 2025 financial results on November 5, 2025, after U.S. markets close. A conference call and audio webcast will follow at 4:30 p.m. ET for management to discuss the results and provide company updates. ADMA specializes in manufacturing and marketing specialty biologics intended for patients with immune deficiencies. They currently offer three FDA-approved products and are developing additional therapies.
Read more →ADMAADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q
ADMA Biologics reported a strong second quarter for 2025, achieving a total revenue of $122 million, marking a 14% increase year-over-year. Adjusted net income saw a remarkable growth of 85% compared to the prior year, fueled by effective cost management and operational efficiencies. The company has begun commercial-scale manufacturing with an FDA-approved yield enhancement process, indicating a potential for increased production capacity. Furthermore, ADMA secured a $300 million syndicate debt refinancing to enhance its financial flexibility and reduce borrowing costs. Overall, the firm is optimistic about sustaining growth into the second half of 2025 and beyond.
Read more →ADMAADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
ADMA Biologics, Inc. will announce its second quarter 2025 financial results on August 6, 2025, after the market closes. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss these results and other updates. Participants will need to register for the call to access dial-in numbers and PINs.
Read more →ADMAADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue (1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Incom
ADMA Biologics reported strong financial results for the first quarter of 2025, showcasing a 40% year-over-year increase in total revenue to $114.8 million. The company's GAAP net income rose by 51% to $26.9 million, underscoring solid operational performance. Significant contributions to revenue growth came from increased sales of the ASCENIV product. Additionally, ADMA announced an FDA-approved yield enhancement production process expected to positively impact future financial performance.
Read more →ADMAADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
ADMA Biologics, Inc. announced it will report its financial results for the first quarter of 2025 on May 7, 2025, following the close of U.S. financial markets. A live conference call and audio webcast will be hosted by the management team at 4:30 p.m. ET to discuss the results and company updates. ADMA is known for its commitment to manufacturing and developing specialty biologics aimed at treating immunodeficient patients.
Read more →ADMA▲ +12.1%on this newsshared move
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
ADMA Biologics has received FDA approval for its innovative yield enhancement production process, which is expected to increase production output by approximately 20% from the same plasma volume. This milestone is anticipated to significantly boost the company's revenue and earnings trajectory starting in late 2025. The approval underscores ADMA's commitment to advancing plasma fractionation technology and improving access to immune globulin therapies for patients.
Read more →ADMAADMA Biologics Statement on Tariffs
ADMA Biologics has issued a statement regarding recent tariffs, asserting that its fully U.S.-based manufacturing and supply chain will not be affected. The CEO emphasized that the company’s domestic operations provide a strategic advantage, ensuring resilience and compliance. ADMA aims to leverage national economic incentives and deliver high-quality products to its customers.
Read more →ADMAADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including a
ADMA Biologics recently announced strong financial results for the fourth quarter and full year 2024, showcasing a 65% year-over-year revenue increase to $426.5 million and significant improvements in net income and adjusted EBITDA. The company highlighted the successful implementation of long-term high-titer plasma supply agreements as a critical factor in its growth trajectory and upcoming operational strategies. Additionally, it provided optimistic revenue and net income guidance for FY 2025 and 2026, aiming for over $1 billion in annual revenue before 2030. The anticipated FDA approval for an enhanced production process further supports ADMA's growth outlook.
Read more →ADMA▲ +6.2%on this newsshared move
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
ADMA Biologics will participate in the Raymond James Institutional Investor Conference on March 5, 2025. CEO Adam Grossman will lead a fireside chat, providing insights into the company’s operations and future plans. A live audio webcast will be available for investors, showcasing ADMA's commitment to transparency and investor engagement.
Read more →ADMAADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
ADMA Biologics, Inc. has announced that it will report its financial results for the fourth quarter and full year 2024 on March 3, 2025. The reporting will occur after the U.S. financial markets close, followed by a live conference call at 4:30 p.m. ET to discuss the results and other updates. ADMA is known for its development of specialty biologics for immunodeficient patients and currently markets three FDA-approved plasma-derived products.
Read more →ADMA▼ -11.2%on this news
ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology January 2025 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements" pursuant to t
ADMA Biologics is advancing its position in the specialty biologics sector, focusing on innovative immunotechnology and the commercialization of its products. The company has achieved FDA approval for three products, enabling it to navigate the competitive landscape effectively. Future growth is anticipated through the expansion of its product pipeline and manufacturing capabilities, with a strong focus on serving patients with immune deficiencies. There are forward-looking strategies in place that suggest significant revenue potential as the immune globulin market grows.
Read more →ADMA▼ -11.2%on this news
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update FY 2024 Preliminary Unaudited Total Revenue of Approximately $417-425 Million, Exceeding Previous Guidance of $415 Million YE 2024
ADMA Biologics has announced its preliminary revenue for the full year 2024, estimating between $417 and $425 million, which is above previous guidance of $415 million. The company expects substantial growth in future years, projecting FY 2025 revenue to exceed $485 million and FY 2026 to surpass $600 million. ADMA has secured new high titer plasma supply contracts that are anticipated to support the growth of its ASCENIV product into the late 2030s, and it has submitted a regulatory application for an innovative yield enhancement process that could improve production yields significantly. Overall, the company expresses strong confidence in its growth trajectory and product impact on patients' lives.
Read more →ADMAADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
ADMA Biologics, Inc. announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 13-16, 2025, in San Francisco. The company's presentation will take place on January 13 at 10:30 a.m. PT. ADMA specializes in manufacturing and marketing specialty biologics for immunodeficient patients and operates an FDA-licensed facility in Boca Raton, Florida. The event will feature a live audio webcast, making the presentation accessible to a wider audience.
Read more →ADMAADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital Lowers ADMA's Total Debt to $75 Million, a 29%
ADMA Biologics announced a $30 million paydown of its senior secured term loan, utilizing cash on hand. This payment reduces the company's total gross debt to $75 million and represents a 29% decrease. The CEO expressed optimism that this move will lower interest expenses and support future earnings growth. Additionally, the company aims to optimize its cost of debt and equity capital in the future.
Read more →ADMAADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is conducting an investigation into ADMA Biologics, Inc. on behalf of its stockholders for potential violations of federal securities laws. This follows the unexpected resignation of the company's independent auditor, which resulted in a steep decline of over 20% in the stock price. The firm is encouraging investors to come forward if they have suffered losses or have relevant information regarding these matters. This situation raises concerns about ADMA Biologics' business practices and its impact on shareholders.
Read more →ADMA▲ +14.7%on this newsshared move
ADMA INVESTOR NEWS: ADMA Biologics Investors with Losses May have been Affected by Fraud; Contact BFA Law (Nasdaq:ADMA)
ADMA Biologics is under investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws following the sudden resignation of its auditor, CohnReznick LLP. This event has triggered a drastic stock price drop of more than 20% as of October 10, 2024. Investors are encouraged to seek more information and may have legal recourse. The law firm has a notable history of representing plaintiffs in securities class actions, which adds a layer of concern for current shareholders.
Read more →ADMAADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update 3Q 2024 Total Revenue of $119.8 Million, a 78% Increase Y-o-Y 3Q 2024 GAAP Net Income of $35.9 Million, a 1,300% Increase Y-o-Y 3
ADMA Biologics reported exceptional financial results for the third quarter of 2024, with total revenues of $119.8 million, marking a 78% increase from the previous year. The company achieved a GAAP net income of $35.9 million, reflecting a staggering 1,300% growth year-over-year. Additionally, the firm has improved its financial guidance for both 2024 and 2025, anticipating total revenues of over $415 million and $465 million respectively. However, the company faces challenges with gross margins affected by lower secondary market sales. ADMA advances its S. pneumoniae hyperimmune globulin program, SG-001, which may add significant value if successful.
Read more →ADMAADMA STOCK REPORT: ADMA Biologics Investors are Notified to Contact BFA Law about the Securities Fraud Investigation after Stock Drops 20%
ADMA Biologics, Inc. faces a securities fraud investigation following a significant drop in stock value. The company's stock plummeted over 20% after the unexpected resignation of its independent auditor, CohnReznick LLP, raising concerns among investors. Legal firm Bleichmar Fonti & Auld LLP has encouraged affected investors to seek further information and consider potential legal actions. This development points to serious implications for shareholder confidence and the company's standing in the market.
Read more →ADMAADMA INQUIRY ALERT: A Securities Fraud Investigation has been Initiated against ADMA Biologics into the Auditor Resignation; Investors with Losses are Urged to Contact the Firm (Nasdaq:ADMA)
ADMA Biologics, Inc. is under investigation for potential violations of federal securities laws following the unexpected resignation of its independent outside auditor, CohnReznick LLP. This development has led to a dramatic decline in ADMA's stock price, which fell by more than 20% during trading shortly after the announcement on October 9, 2024. Investors who have suffered losses are being encouraged to seek legal guidance from securities law firm Bleichmar Fonti & Auld LLP, which is pursuing a class action lawsuit.
Read more →ADMAADMA INVESTIGATION: ADMA Biologics Investors with Losses are Notified to Contact BFA Law about Ongoing Securities Fraud Investigation into Auditor Resignation (Nasdaq:ADMA)
Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for possible violations of federal securities laws following the resignation of its auditor, CohnReznick LLP. This unexpected resignation has caused ADMA Biologics' stock to fall over 20%. Investors are urged to seek legal guidance as they may have options available due to this situation. The investigation comes at a time when ADMA is already under scrutiny, raising concerns among shareholders.
Read more →ADMAADMA INVESTIGATION NOTICE: ADMA Biologics Stock Plummets 20% after Auditor Resigns; Investors are Notified to Contact BFA Law (Nasdaq:ADMA)
ADMA Biologics, Inc. is facing an investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws after the unexpected resignation of its auditor, CohnReznick LLP. This development has led to a significant decline in ADMA's stock price, which fell by over 20%. Investors are encouraged to seek legal options regarding their investments amidst this crisis, which reflects serious concerns about the company's financial governance and future stability.
Read more →ADMAADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
ADMA Biologics, Inc. will announce its financial results for the third quarter of 2024 on November 7, following the closure of U.S. financial markets. A live conference call and audio webcast will be held at 4:30 p.m. ET that day to discuss the results and other updates. ADMA is known for manufacturing and marketing specialty biologics aimed at immunodeficient patients. The event is accessible via dial-in and also as a live webcast, with an archived replay to be made available afterward.
Read more →ADMAADMA FRAUD ALERT: BFA Law Notifies ADMA Biologics Investors of Ongoing Securities Fraud Investigation after Auditor Resigns and Urges You to Contact the Firm (Nasdaq:ADMA)
Bleichmar Fonti & Auld LLP has launched an investigation into ADMA Biologics for possible violations of federal securities laws following the unexpected resignation of its auditor, CohnReznick LLP. This development has triggered a sharp decline of over 20% in ADMA's stock price. Investors are encouraged to seek legal counsel and submit their information to pursue potential claims against the company. The situation poses significant risks for ADMA Biologics, as the investigation may unravel further compliance issues and legal liabilities.
Read more →ADMAADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased ADMA Biologics Inc securities. This follows the recent resignation of ADMA's independent auditor, CohnReznick LLP, which led to a significant drop in the company's stock price by over 16%. The firm is encouraging affected investors to come forward and assist with the investigation.
Read more →ADMAADMA LEGAL NEWS: ADMA Biologics Investigated for Securities Fraud after Stock Drops 20%; Investors with Losses are Urged to Contact BFA Law (Nasdaq:ADMA)
ADMA Biologics, Inc. is currently being investigated for potential violations of federal securities laws following a significant decline in its stock price. The 20% drop was triggered by the unexpected resignation of its independent outside auditor. Investors who have incurred losses are being encouraged to contact the law firm Bleichmar Fonti & Auld LLP for possible legal actions. This investigation highlights the challenges faced by ADMA in maintaining investor confidence.
Read more →ADMAADMA STOCK ALERT: Why is ADMA Biologics being Sued for Securities Fraud? Investors that Lost Money are Notified to Contact BFA Law after Stock Drops 20% (Nasdaq:ADMA)
ADMA Biologics, Inc. is under investigation for potential violations of federal securities laws following the unexpected resignation of its independent auditor. This event has significantly impacted the company's stock price, leading to a more than 20% decline since October 9, 2024. Investors who lost money as a result of this decline are being informed of their legal options. Leading law firm Bleichmar Fonti & Auld LLP is spearheading the investigation and encourages affected shareholders to seek representation.
Read more →ADMAADMA INVESTIGATION NEWS: The Securities Fraud Investigation into ADMA Biologics, Inc. after Stock Drops 20% is Ongoing; Contact BFA Law if You Lost Money (Nasdaq:ADMA)
ADMA Biologics, Inc. is currently under investigation for potential federal securities law violations following a dramatic stock decline exceeding 20%. This decline was triggered by the unexpected resignation of the company’s outside auditor, CohnReznick LLP. Investors are being encouraged to seek legal recourse, and the law firm Bleichmar Fonti & Auld LLP is actively collecting information from affected shareholders. The investigation reflects serious concerns regarding the company's compliance and financial practices.
Read more →ADMAADMA INVESTIGATION UPDATE: ADMA Biologics Investors are Notified of Securities Fraud Investigation into Auditor Resignation; Contact BFA Law if You Lost Money (Nasdaq:ADMA)
ADMA Biologics, Inc. is currently facing a securities fraud investigation following the unexpected resignation of its auditor, CohnReznick LLP. This event has led to a significant decline in the company's stock price, dropping more than 20% shortly after the announcement. In light of the investigation, Bleichmar Fonti & Auld LLP is encouraging impacted investors to seek additional information. The firm specializes in representing plaintiffs in securities class actions and is offering contingent legal services for affected stakeholders.
Read more →ADMAADMA FRAUD NOTICE: Lost Money on Your ADMA Biologics, Inc. Securities? Contact BFA Law about its Investigation into the Company after Auditor Resigns (Nasdaq:ADMA)
ADMA Biologics, Inc. is under investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws following the resignation of its independent auditor, CohnReznick LLP. This unexpected event has triggered a severe decline in the company's stock price, dropping over 20% shortly after the announcement. Investors in ADMA Biologics are encouraged to seek legal advice regarding possible damages due to this situation. The law firm’s investigation highlights serious concerns about the company’s financial practices and investor protection.
Read more →ADMAADMA Biologics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
Block & Leviton has initiated an investigation into ADMA Biologics, Inc. for possible securities law violations following a significant drop in stock price. On October 10, 2024, the company reported that its auditor, CohnReznick, was resigning, leading to a nearly 20% decline in share value. Investors who have experienced losses may contact Block & Leviton to explore options for recovering their investments. The firm is recognized for representing investors in securities class action lawsuits.
Read more →ADMAADMA LEGAL NOTICE: ADMA Biologics, Inc. is being Investigated for Securities Fraud after Auditor Resignation; Investors with Losses are Urged to Contact BFA Law (Nasdaq:ADMA)
ADMA Biologics, Inc. is currently under investigation for potential securities fraud following the abrupt resignation of its auditor, CohnReznick LLP, which led to a more than 20% decline in its stock price. The leading securities law firm, Bleichmar Fonti & Auld LLP, is urging investors to come forward if they have experienced losses. This situation raises significant concerns about the company's compliance with federal securities laws and its impact on shareholder value.
Read more →ADMAADMA SHAREHOLDER ALERT: ADMA Biologics, Inc. is Under Investigation for Securities Fraud after Auditor Resignation and 20% Stock Drop; Investors are Urged to Contact BFA Law (Nasdaq:ADMA)
ADMA Biologics, Inc. is under investigation for potential securities fraud following the unexpected resignation of its independent auditor, CohnReznick LLP. This development led to a significant decrease in the stock price, plunging more than 20% on October 10, 2024. Investors are being urged to seek further information and consider legal options regarding their investments. The situation raises significant concerns about the company's financial transparency and stability.
Read more →ADMAADMA FRAUD ALERT: BFA Law is Investigating ADMA Biologics, Inc. for Securities Fraud after Stock Drops 20%; Investors with Losses are Urged to Contact the Firm (Nasdaq:ADMA)
Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics, Inc. for potential securities fraud after a significant 20% drop in the company's stock price. This decline followed the unexpected resignation of the company's independent auditor, CohnReznick LLP, on October 9, 2024. Investors are encouraged to reach out for more information, as the firm suggests legal options may be available for those affected by the stock decline.
Read more →ADMA▼ -16.3%on this newsshared move
ADMA Biologics, Inc. Investors: Company Investigated by the Portnoy Law Firm
ADMA Biologics, Inc. is currently under investigation by the Portnoy Law Firm for potential securities fraud, prompting shareholders to consider legal action to recover losses. The law firm is offering complimentary case evaluations for affected investors. This investigation follows a significant drop in ADMA's share price, which fell over 18% after the company announced that CohnReznick would no longer serve as its independent registered accounting firm. The situation indicates growing concerns among investors about the company's corporate governance.
Read more →ADMA▼ -16.3%on this newsshared move
ADMA Biologics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm’s Investigation
Block & Leviton is investigating ADMA Biologics, Inc. for potential securities law violations following a nearly 20% decline in share value after the resignation of its independent auditor. The firm is reaching out to investors who have lost money in ADMA Biologics to explore potential recovery options. Potential plaintiffs are encouraged to contact the firm for assistance regarding their investment losses. Block & Leviton has a reputation for recovering funds for defrauded investors, making them a key resource for affected shareholders.
Read more →ADMAADMA Biologics Set to Join S&P SmallCap 600 Index
ADMA Biologics announced its inclusion in the S&P SmallCap 600 index, effective September 23, 2024. This recognition is seen as a significant milestone for the company, as it aims to increase its visibility in the investment community and improve the liquidity of its shares. ADMA focuses on developing and marketing specialty biologics for immunodeficient patients and possesses several FDA-approved products in this niche sector.
Read more →ADMA▼ -5.9%on this news
ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
ADMA Biologics, Inc. announced that Adam Grossman, the President and CEO, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference in New York on September 17, 2024. The event will include a live audio webcast available on the company’s investor website, with an archived version to be provided shortly after the event. This participation underscores ADMA's commitment to engaging with investors and promoting its specialty biologics offerings for immunodeficient patients.
Read more →ADMAADMA Biologics Announces Partial Paydown of Revolving Credit Facility Cash on Hand Utilized to Repay $30 Million of Revolving Credit Facility to Ares Capital with No Prepayment Penalties Lowers ADMA's Total Debt to $105
ADMA Biologics announced a partial paydown of its revolving credit facility, utilizing $30 million of cash on hand. This repayment reduces ADMA's total gross debt to $105 million, marking a 22% decrease. The company expects that this reduction in debt will lead to lower interest expenses and support its earnings growth outlook. CEO Adam Grossman expressed confidence in the company's sustained growth and cash generation prospects.
Read more →ADMA▲ +6.5%on this news· ran to +51% by day 3
ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update 2Q 2024 Total Revenue of $107.2 Million, a 78% Increase Y-o-Y 2Q 2024 GAAP Net Income of $32.1 Million, a $38.4 Million Increase
ADMA Biologics reported impressive financial results for the second quarter of 2024, with total revenue hitting $107.2 million, a 78% increase compared to the previous year. The company also marked a significant improvement in GAAP net income, reaching $32.1 million, up from a loss in the same quarter last year. ADMA increased its revenue guidance for fiscal years 2024 and 2025, indicating continued optimistic growth prospects. The company focuses on addressing the needs of immunodeficient patients and leverages its innovative biologics manufacturing processes to enhance output.
Read more →ADMAADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
ADMA Biologics, Inc. will report its second quarter 2024 financial results on August 8, 2024, after market close. A conference call and audio webcast will follow at 4:30 p.m. ET for discussion of the results and updates. The company specializes in manufacturing and marketing biologics for immunodeficient patients, holding several FDA approvals and patents relevant to its product portfolio. This upcoming event highlights ADMA's ongoing engagement with investors and commitment to its responsibilities in the biopharmaceutical industry.
Read more →ADMAADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology May 2024 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements," pursuant to the
ADMA Biologics is focusing on enhancing its position in the specialty biologics market by developing and commercializing innovative immune globulin products. With three FDA-approved offerings and a robust pipeline, the company aims to capitalize on the growing immune globulin market, which is expected to see significant growth in the coming years. ADMA also emphasizes its vertically integrated supply chain and advanced manufacturing capabilities as key competitive advantages.
Read more →ADMAADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update 1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y
ADMA Biologics reported strong financial results for the first quarter of 2024, achieving total revenues of $81.9 million, a 44% increase compared to the same period last year. The company also reported a GAAP net income of $17.8 million, an increase of $24.6 million from a loss in the prior year. Additionally, ADMA raised its revenue and net income guidance for 2024 and 2025, underscoring confidence in its growth trajectory. The company credits significant growth to the utilization of ASCENIV and advancements in its immunoglobulin products.
Read more →ADMAADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
ADMA Biologics, an end-to-end commercial biopharmaceutical company, announced it will report its first quarter 2024 financial results on May 9, 2024. The report will occur after the U.S. financial markets close, followed by a live conference call hosted by the management team to discuss outcomes and company updates. ADMA is known for producing specialty biologics aimed at treating immunodeficient patients.
Read more →ADMAADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV & BIVIGAM FDA Approval Provides for Room Temperature (25 C) Storage Conditions for up to 4 Weeks at Any Point During the
ADMA Biologics has announced the FDA's approval of extended room temperature storage conditions for its products ASCENIV and BIVIGAM. The approval allows these products to be stored at 25°C for up to four weeks at any time during their 36-month shelf life. This change is expected to improve inventory management and accessibility to healthcare providers, especially those limited by cold chain storage capabilities. The products are now commercially available under these new conditions.
Read more →ADMAADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology March 2024 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements," pursuant to th
ADMA Biologics is advancing its position in the specialty biologics market by leveraging its innovative immunotechnology. The company emphasized its commitment to expanding its product portfolio and improving supply chain capabilities. With three FDA-approved products and a focus on addressing the growing demand in the immunoglobulin market, ADMA aims for significant growth in the coming years. However, it faces challenges related to regulatory approvals and reliance on external plasma sources.
Read more →ADMAADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update 4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA (1) of $18
ADMA Biologics reported strong financial results for the fourth quarter and full year 2023, highlighting total revenues of $73.9 million for Q4 and $258.2 million for the year, marking an increase of approximately 68% year-over-year. The company recorded its first positive adjusted net income for the full year, with upward revisions to revenue and EBITDA guidance for 2024 and 2025. Despite the positive overall performance, ADMA faced a net loss of $17.6 million for Q4 2023 and a total net loss of $28.2 million for the year, primarily due to a loss on extinguishment of debt. The company aims to advance innovative growth opportunities within its operations, particularly targeting immune-deficient patient segments and expanding its product portfolio.
Read more →ADMAADMA Biologics Announces CFO Transition Executive Search Initiated for CFO Replacement RAMSEY, N.J. and
ADMA Biologics has announced the transition of Brian Lenz from CFO to a consulting role effective April 1, 2024. Adam Grossman, the company's CEO, expressed gratitude for Lenz's contributions over his 11-year tenure, which included guiding the company towards profitability and the expansion of its product offerings. An executive search for Lenz's replacement has been initiated to maintain leadership stability. The company continues to produce three FDA-approved biologics aimed at treating immunodeficient patients.
Read more →ADMAADMA Biologics Announces CFO Transition
ADMA Biologics announced that Brian Lenz will transition from his role as CFO to a consulting position effective April 1, 2024. Adam Grossman, the company's President and CEO, expressed gratitude for Lenz's contributions during his 11-year tenure, emphasizing his role in the company's growth and successful financing initiatives. Grossman will take over as Interim CFO while an executive search for a permanent replacement is initiated. ADMA manufactures and markets specialty biologics for immunodeficient patients, holding multiple FDA approvals.
Read more →ADMAADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
ADMA Biologics, Inc. has announced that it will release its fourth quarter and full year 2023 financial results on February 28, 2024. This event will take place after the U.S. financial markets close, followed by a live conference call hosted by the management team. Participants can register for the call through the company’s website, where an archived version will also be available post-event. ADMA is recognized for its specialty biologics aimed at treating immunodeficient patients and other infectious disease prevention.
Read more →ADMAADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes ADMA Successfully Utilized ADMAlytics' New Capabiliti
ADMA Biologics has successfully implemented an innovative AI program, ADMAlytics, designed to optimize its production processes. This AI initiative combines generative AI and machine learning to enhance efficiency, with the first successful batch of ASCENIV produced using this technology. The company anticipates broad implementation across its operations to further improve efficiency and support its growth trajectory. Leadership at ADMA has emphasized the importance of continuous innovation in its specialty biologics production to maintain patient care continuity.
Read more →ADMA▲ +9.3%on this news
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update 4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million
ADMA Biologics has reported strong preliminary unaudited revenues for the fourth quarter and full year of 2023, estimating $72-74 million and $256-258 million respectively. The company has increased its financial guidance for the upcoming years, projecting over $320 million in revenue for FY 2024 and $370 million for FY 2025. Adam Grossman, CEO, emphasized robust business trends and identified growth opportunities including enhancements in manufacturing yields and a new S. pneumonia hyperimmune program. These developments position ADMA for sustained growth and improved profitability going forward.
Read more →ADMA▲ +9.3%on this news
ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology January 2024 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements," pursuant to
ADMA Biologics is advancing its specialty biologics through groundbreaking immunotechnology, positioning itself uniquely in the U.S. immunoglobulin market. The company's strategy includes expanding its pipeline of differentiated immune globulin products and solidifying its commercial infrastructure. With three FDA-approved products and a robust plasma collection network, ADMA aims to capture significant market share in a competitive and growing landscape. The company highlights its vertically integrated supply chain and innovative manufacturing processes as key differentiators in the biopharma industry.
Read more →ADMAADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management New $135 Million Credit Facility Replaces Existing $159 Million Credit Facility, a 15% Decrease in Total Debt Furth
ADMA Biologics has announced a $135 million non-dilutive refinancing agreement with Ares Management, replacing an existing $159 million credit facility. This refinancing results in a 15% reduction in total debt and is expected to support the company’s growth and earnings outlook. ADMA CEO Adam Grossman highlighted the significance of this move in enhancing the company's financial health while maintaining current shareholder equity. The agreement further cements ADMA's strategic direction as it prepares for growth in 2024.
Read more →ADMAADMA Biologics Announces FDA Approval for BIVIGAM in the Pediatric Patient Setting for Those 2 Years of Age and Older Signifies the Successful Fulfillment of BIVIGAM's Post Marketing Commitments as Part of the Original B
ADMA Biologics has announced that the FDA has approved their product BIVIGAM for use in pediatric patients aged 2 years and older. This approval expands the indication for BIVIGAM, which was previously limited to patients aged 12 and older. The update follows successful post-marketing commitments related to pediatric assessments. The company expressed gratitude towards the PI disease community and highlighted the ongoing dedication of its team in advancing the clinical program.
Read more →ADMAADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD FDA Approval Signifies the Accomplishment of ADMA's Corporate Goal of Plasma Supply Self-Sufficiency RAMSEY, N.J., BOCA
ADMA BioCenters has received FDA approval for its tenth plasma collection center in Laurel, Maryland, which began operations earlier in 2023. This facility enables ADMA to achieve its objective of plasma supply self-sufficiency and boosts its capacity for producing specialty plasma-derived biologics. The center features advanced technology aimed at improving donor experience and is expected to contribute to ADMA's revenue and profitability growth.
Read more →ADMAADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update 3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase First-Time Positive GAAP Net Income of $2.6 Million First-Time Posit
ADMA Biologics reported significant financial results for the third quarter of 2023, with total revenues reaching $67.3 million, a 64% increase compared to the previous year. The company achieved its first-ever positive GAAP net income of $2.6 million and recorded an impressive growth in Adjusted EBITDA of 98% sequentially. ADMA has also increased its revenue forecasts for the years ahead, reflecting strong performance driven by sales of its immunoglobulin products. The company is optimistic about its future growth prospects in the biopharmaceutical market.
Read more →ADMAADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023
ADMA Biologics, Inc. has announced the upcoming release of its third quarter 2023 financial results on November 8, 2023, following the close of U.S. financial markets. The company's management will host a live conference call at 4:30 p.m. ET to discuss the financial outcomes and provide updates. ADMA specializes in manufacturing and marketing specialty plasma-derived biologics designed for immunodeficient patients and has multiple FDA-approved products.
Read more →ADMAADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update 2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA(1) of $6.4 Million, a 160% Q-o-Q Improvement
ADMA Biologics has reported robust financial results for the second quarter of 2023, showcasing a total revenue of $60.1 million, which reflects a 77% year-over-year increase. The company's Adjusted EBITDA reached $6.4 million, marking a significant 160% improvement compared to the first quarter of 2023. Furthermore, ADMA has increased its revenue forecasts for the next three fiscal years, indicating a positive outlook driven by its innovative business model and expanded market penetration in immune deficient patient populations. However, the company continues to face challenges, including a net loss and a decline in third-party plasma sales.
Read more →ADMAADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
ADMA Biologics, an end-to-end biopharmaceutical company, has announced it will release its second quarter financial results on August 9, 2023. Following the release, management will host a conference call at 4:30 p.m. ET to discuss the results and provide updates on the company. ADMA currently has three FDA-approved biologics aimed at treating immunodeficient patients and operates a plasma collection facility in Florida.
Read more →ADMAADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Tra
ADMA Biologics has received FDA approval for its ninth plasma collection center located in Dallas, Georgia. This approval is in line with the company's strategic goal of achieving plasma supply self-sufficiency and continued revenue growth. The Dallas facility, operational since the third quarter of 2022, is now licensed to collect and distribute human source plasma. ADMA is aiming to have all ten of its planned plasma centers FDA-licensed by the end of 2023, enhancing its growth prospects in the biopharmaceutical sector.
Read more →ADMAADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update 1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement Achieved Mile
ADMA Biologics reported strong financial results for Q1 2023, with total revenues reaching $57 million, marking a 96% year-over-year increase. The company achieved its first positive Adjusted EBITDA of $2.5 million earlier than expected and revised its total revenue guidance for the year upwards to over $220 million. Although there is an overall improvement in financial metrics, ADMA still recorded a net loss of $6.8 million. The company is focusing on growth initiatives that may further enhance profitability in the coming years.
Read more →ADMA▲ +5.5%on this news
ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023
ADMA Biologics has announced that it will report its financial results for the first quarter of 2023 on May 10, 2023. A conference call will follow the release to discuss the results and provide additional updates. The company specializes in plasma-derived biologics, and it continues to manufacture and market several FDA-approved products for the treatment of immunodeficient patients.
Read more →ADMAADMA Biologics Announces Amendment to Credit Agreement . Reduces Nominal Interest Rate by 1% Provides for Improved Prepayment Flexibility Total Debt Level Unchanged Favorable Amendment Enabled by Strengthened Financial O
ADMA Biologics has amended its senior credit facility with Hayfin Capital Management, achieving a 1% reduction in the nominal interest rate and improved prepayment flexibility. The total debt level remains unchanged, but the amendment reflects the company's strengthened financial outlook as it works towards profitability. The changes are expected to lower ADMA's capital costs and allow for financial flexibility, potentially positioning the company for growth and strategic opportunities in the near future.
Read more →ADMAADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update 4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase 4Q2022 Gross Profit of $14 Million, an $11 Million Y-o-
ADMA Biologics reported a strong financial performance for the fourth quarter and full year of 2022, with total revenues reaching $50 million, a remarkable 90% increase year-over-year. The company anticipates continued growth, projecting total revenue for FY 2023 to exceed $210 million and expecting positive EBITDA by the second half of the year. Despite a consolidated net loss of $12.2 million for Q4 2022, the company has seen improvements in gross profits, primarily driven by sales of its ASCENIV product and a growing customer base. ADMA's commitment to the immune deficient patient segment positions it well for future growth.
Read more →ADMAADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
ADMA Biologics, Inc. announced that it will report its fourth quarter and full year 2022 financial results on March 23, 2023, after U.S. markets close. A live conference call will be held at 4:30 p.m. ET to discuss these results and provide updates about the company. Interested parties can register for the call to receive access details and will also be able to access a live audio webcast through the company's investor website.
Read more →ADMAADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-T
ADMA BioCenters has received FDA approval for its eighth plasma collection center in Hammond, Louisiana. This facility is now licensed to collect human source plasma for manufacturing purposes, aligning with the company's aim for plasma self-sufficiency and revenue growth. ADMA plans to have all ten collection centers licensed by the end of 2023. The new center features advanced collection technology and improved donor amenities, contributing to a safer and more efficient donation process.
Read more →ADMAADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year
ADMA Biologics has announced preliminary, unaudited revenue figures for the fourth quarter and full year of 2022, reporting substantial year-over-year improvements. The company expects fourth quarter revenues to fall between $49-$50 million, up 89% from 2021, and a total of approximately $153-$154 million for the full year, marking a 90% increase over the previous year. Looking ahead, ADMA projects 2023 revenues to exceed $210 million, indicating a growth rate of around 40%. The company also anticipates achieving its first positive EBITDA during the latter half of 2023, supported by strategic initiatives and market positioning.
Read more →ADMAADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM
FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life Provides for improved inventory management and ease of product administration to patients Approval
Read more →ADMAADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock RAMSEY, N.J. and BOCA RATON, Fla., December 7,2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) ("ADMA" or the "Company"), an
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock RAMSEY, N.J. and BOCA RATON, Fla., December 7,2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated
Read more →ADMAADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares RAMSEY, N.J. and BOCA RATON, Fla., December 9,2022 (GLOBE NEWSWIRE) -- ADMA Bi
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares RAMSEY, N.J. and BOCA RATON, Fla., December 9,2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) ("ADMA" or the "Company"), an e
Read more →ADMA▲ +8.8%on this newsshared move
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today pri
Read more →ADMAADMA Biologics Announces Proposed Public Offering of Common Stock
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today an
Read more →ADMAADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million RAMSEY, N.J. and
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million RAMSEY, N.J. and BOCA RATON, FL, December 6, 2022 - ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"),
Read more →ADMA▼ -5.4%on this news· ran to +27% by day 3
ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update 3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Inc
ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update 3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase Raising FY 2022 Total Revenue Guidance to $145 Mill
Read more →ADMAADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022
Conference Call Scheduled for November 9, 2022, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, mark
Read more →ADMAADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains
ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Lice
Read more →ADMAADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update 2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase Grew 2Q2022 Gross Profit to $7.8 Million, Up 112% Over 1Q2022 Nar
ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update 2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase Grew 2Q2022 Gross Profit to $7.8 Million, Up 112% Over 1Q2022 Narrowed 2Q2022 Net Losses to $13.8 Million, a 45% Improveme
Read more →ADMAADMA Biologics to Report Second Quarter 2022 Financial Results on August 10, 2022
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today an
Read more →ADMA▲ +11.3%on this news
ADMA BioCenters Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SC FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company is on-tr
ADMA BioCenters Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SC FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company is on-track to have all 10 plasma collection centers FDA-approved
Read more →ADMAADMA Biologics Announces Addition to the Russell 2000 Index
Ramsey, N.J. and Boca Raton, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today an
Read more →ADMA▼ -11.2%on this news
ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update First Quarter 2022 Total Revenues Were Approximately $29.1 Million, an 81% Increase Over First Quarter 2021 Increases Full Year 2
ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update First Quarter 2022 Total Revenues Were Approximately $29.1 Million, an 81% Increase Over First Quarter 2021 Increases Full Year 2022 Total Revenue Guidance to $130 Million or More From $
Read more →ADMAADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022
RAMSEY, N.J. and BOCA RATON, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today ann
Read more →ADMA▲ +8.7%on this news· ran to +21% by day 3
ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV & BIVIGAM from 24 to 36 Months Approval of 36-month shelf life encompasses all ASCENIV & BIVIGAM vial sizes, production scales, as well as internal
ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV & BIVIGAM from 24 to 36 Months Approval of 36-month shelf life encompasses all ASCENIV & BIVIGAM vial sizes, production scales, as well as internal and external fill-finishing Extended shelf life ASCENIV &
Read more →ADMAADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management Full Year 2021 Total Revenues of Approximately $81
ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020 Gross Profita
Read more →ADMA▼ -8.8%on this newsshared move
ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022
RAMSEY, N.J. and BOCA RATON, Fla., March 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today a
Read more →ADMAADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company positioned to
ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company positioned to meet or exceed target of 10 or more FDA-approved plasma c
Read more →ADMAADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest
ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Full Year 2021 Pr
Read more →ADMAADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC FDA approval positions Company to meet or exceed target of ten or more FDA-licensed plasma collection centers by ye
ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC FDA approval positions Company to meet or exceed target of ten or more FDA-licensed plasma collection centers by year-end 2023 RAMSEY, N.J., BOCA RATON, Fla. and GOOSE CREEK
Read more →ADMAADMA Biologics Adopts Limited Duration Stockholder Rights Plan RAMSEY, N.J. and
ADMA Biologics Adopts Limited Duration Stockholder Rights Plan RAMSEY, N.J. and BOCA RATON, Fla., December 21, 2021 - ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-de
Read more →ADMAADMA Biologics Provides Update on Global Intellectual Property Portfolio Extends Existing U.S. Patent with Granted European Patent for Treatment and Prevention of S. Pneumococcal Infections with a Hyperimmune Globulin Re
ADMA Biologics Provides Update on Global Intellectual Property Portfolio Extends Existing U.S. Patent with Granted European Patent for Treatment and Prevention of S. Pneumococcal Infections with a Hyperimmune Reinforces Existing and Pending IP that Provides for Spiking' IG Pool
Read more →ADMAADMA Biologics Realizing the Potential of Plasma-Derived Therapieswith Groundbreaking Immunotechnology December 2021 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements," pursua
ADMA Biologics Realizing the Potential of Plasma-Derived Therapieswith Groundbreaking Immunotechnology December 2021 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements," pursuant to the safe harbor provisions of the Private Securitie
Read more →ADMAADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today an
Read more →ADMAADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Con
ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction RAMSEY, N.J., BOCA RATON, FL and Myrtle Beach, S
Read more →ADMAADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third
ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third Quarter 2020 Achieved First-Time Positive Gross Profit N
Read more →ADMA▲ +5.7%on this news
ADMA Biologics to Report Third Quarter 2021 Financial Results on November 10, 2021
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today an
Read more →ADMAADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares RAMSEY, NJ and
ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares RAMSEY, NJ and BOCA RATON, FL, October 25, 2021 -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical comp
Read more →ADMA▲ +5.8%on this newsshared move
ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today an
Read more →ADMA▲ +9%on this news· ran to +22% by day 3shared move
ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock RAMSEY, N.J. and
ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock RAMSEY, N.J. and BOCA RATON, Fla., October 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicate
Read more →ADMAADMA Biologics Announces a Poster Presentation at the 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization Conference
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today an
Read more →ADMAADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D. RAMSEY, N.J. and BOCA RATON, Fla .
ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D. RAMSEY, N.J. and BOCA RATON, Fla., October 18, 2021 - ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to ma
Read more →ADMAADMA Biologics Announces the Presentation of Real-World Experience in the Management of Respiratory Syncytial Virus (RSV) Presented at IDWeek 2021
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today an
Read more →ADMA▲ +5.3%on this newsshared move
ADMA Biologics Announces Presentation on Respiratory Viral Infections at IDWeek 2021
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today an
Read more →ADMAADMA Biologics to Virtually Participate in the Cantor Healthcare Conference
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced t
Read more →ADMA▼ -7.1%on this news
ADMA Biologics Receives FDA Approval for VanRx Aseptic Fill-Finish Machine and Related Operations
Expected to Provide Improved Gross Margins, Enhanced Patient Supply Consistency, Accelerated Inventory Production Cycle Time and Increased Control and Visibility of Commercial Product Lot Releases Additional Opportunity for Contract Manufacturing Filling Services and Capabilitie
Read more →ADMAADMA Biologics to Virtually Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 02, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced t
Read more →ADMAADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Maryville, TN RAMSEY, N.J., BOCA RATON, Fla. and
ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Maryville, TN RAMSEY, N.J., BOCA RATON, Fla. and MARYVILLE, Tenn. - August 16, 2021 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated
Read more →ADMAADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments Achieved Record Total Revenues of $17.8 Million in Second Quarter 2021, a 129% Increase Over Second Q
ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments Achieved Record Total Revenues of $17.8 Million in Second Quarter 2021, a 129% Increase Over Second Quarter 2020 Narrowed Gross and Net Losses Year-over-Year
Read more →ADMAADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics’ Persona Technology for NexSys Plasma Collection System
RAMSEY, N.J. and BOCA RATON, Fla. and CONYERS, Ga., Aug. 10, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announce
Read more →ADMAADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM and NABI-HB ADMA Expands Commercial IG Product Offering with Additional BIVIGAM and NABI-HB Vial Sizes BIVIGAM 100 mL Vial and
ADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM and NABI-HB ADMA Expands Commercial IG Product Offering with Additional BIVIGAM and NABI-HB Vial Sizes BIVIGAM 100 mL Vial and NABI-HB 1 mL Vial Now Commercially Available to U.S. Healt
Read more →ADMAADMA Biologics to Report Second Quarter 2021 Financial Results on August 11, 2021
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today an
Read more →ADMAADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection Approval for VanRx Fill-Finish Machine Expected in the Second Half of 2021 All Supply Chain Robustness Initiatives Rema
ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection Approval for VanRx Fill-Finish Machine Expected in the Second Half of 2021 All Supply Chain Robustness Initiatives Remain on Schedule RAMSEY, NJ and BOCA RATON, FL - July 20, 2
Read more →ADMAADMA Biologics to Participate in the Raymond James Human Health Innovation Virtual Conference
RAMSEY, N.J. and BOCA RATON, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced th
Read more →ADMAADMA Biologics to Participate in the Jefferies Virtual Healthcare Conference
RAMSEY, N.J. and BOCA RATON, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced tha
Read more →ADMAADMA Biologics Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress and Accomplishments Achieved First Quarter 2021 Total Revenues of $16.0 Million, a 57% Increase Over First Quarter 2020 S
ADMA Biologics Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress and Accomplishments First Quarter 2021 Total Revenues of $16.0 Million, a 57% Increase Over First Quarter 2020 Significantly Expanded Total Asset Value to $235.7 Million, Includ
Read more →ADMAADMA Biologics to Report First Quarter 2021 Financial Results on May 12, 2021
RAMSEY, N.J. and BOCA RATON, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it wi
Read more →ADMAADMA Biologics Receives FDA Approval for Increased IVIG Production Scale ADMA Increases Total Forecasted Plant Manufacturing Capacity from 400,000 Liters up to 600,000 Liters and Increases Total Forecasted Peak Revenues
ADMA Biologics Receives FDA Approval for Increased IVIG Production Scale ADMA Increases Total Forecasted Plant Manufacturing Capacity from 400,000 Liters up to 600,000 Liters and Increases Total Forecasted Peak Revenues in Excess of $300 Million Enhanced Gross Margins and Cos
Read more →ADMAADMA Biologics Opens Newest ADMA BioCenters Plasma Collection Facility in Goose Creek, S.C.
RAMSEY, N.J. and BOCA RATON, Fla. and GOOSE CREEK, S.C., April 26, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, an
Read more →ADMAADMA Biologics Announces Poster Presentation Highlighting Pharmacoeconomic Burden of HIV and HBV Infection in Sexual Assault Patients at the 2021 Academy of Managed Care Pharmacy Virtual Annual Meeting
Poster Presentation Highlights the Unmet Patient Need and Medical Cost Burden Associated with Hepatitis B Infection Healthcare Costs Associated with HBV and HIV are Approximately at Parity; HBV Carries 50-100 Times Greater Transmission Risk Compared to HIV Pharmacoeconomic Anal
Read more →ADMAADMA Biologics Reports Fourth Quarter and Full Year 2020 Financial Results Achieved Full Year 2020 Total Revenues of $42.2 Million, a 44% Increase Over Full Year 2019 Accelerated ADMA BioCenters Plasma Collection Network
Reports Fourth Quarter and Full Year 2020 Financial Results Full Year 2020 Total Revenues of $42.2 Million, a 44% Increase Over Full Year 2019 Accelerated ADMA BioCenters Plasma Collection Network Expansion Guidance; Anticipates Having 10 or More Plasma Collection Centers in O
Read more →ADMAADMA Biologics to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021
RAMSEY, N.J. and BOCA RATON, Fla., March 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it
Read more →ADMAADMA Biologics to Participate in the Jefferies Virtual Plasma Summit
RAMSEY, N.J. and BOCA RATON, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today a
Read more →ADMAADMA Biologics Expands Global Regulatory Approval Presence and Announces FDA Approval to Commence Hepatitis B Plasma Collections
RAMSEY, N.J. and BOCA RATON, Fla. and KENNESAW, Ga., March 03, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today
Read more →ADMAADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting
Poster Presentation Highlights the Need for a Polyclonal Hyperimmune Globulin Targeting S. Pneumoniae to Bridge Vaccination and Seroconversion Across Multiple Serotypes By Using as an Add-On with a Vaccine or Antibiotics, This Therapeutic Strategy has the Potential to Improve S.
Read more →ADMAADMA Biologics to Participate in Raymond James Institutional Investor Conference
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today an
Read more →ADMAADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Knoxville, TN RAMSEY, N.J., BOCA RATON, Fla. and
Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Knoxville, TN RAMSEY, N.J., BOCA RATON, Fla. and KNOXVILLE, Tenn. - February 1, 2021 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufact
Read more →ADMAADMA Biologics Receives Unique Permanent J-Code for ASCENIV RAMSEY, N.J. and
ADMA Biologics Receives Unique Permanent RAMSEY, N.J. and BOCA RATON, FL., January 26, 2021 - ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today
Read more →ADMAADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2020 Revenues and Provides 2021 Strategic Outlook Achieved Fourth Quarter 2020 Preliminary Unaudited Total Revenues of $13.9 Million, the Highest Revenue
Biologics Announces Preliminary Fourth Quarter and Full Year 2020 Revenues and Provides 2021 Strategic Outlook Quarter 2020 Preliminary Unaudited Total Revenues of $13.9 Million, the Highest Revenue Quarter for the Company Since Inception Preliminary Unaudited Total Revenues of
Read more →ADMAADMA Biologics Receives Unique Temporary C-Code and Pass-Through Payment Status for ASCENIV RAMSEY, N.J. and
ADMA Biologics Receives Unique Temporary C-Code and Pass-Through Payment Status for ASCENIV RAMSEY, N.J. and BOCA RATON, FL., January 4, 2021 - ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and de
Read more →ADMAADMA BIOLOGICS ADOPTS LIMITED DURATION STOCKHOLDER RIGHTS PLAN RAMSEY, N.J. and
ADMA BIOLOGICS ADOPTS LIMITED DURATION STOCKHOLDER RIGHTS PLAN RAMSEY, N.J. and BOCA RATON, Fla., December 16, 2020 - ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-
Read more →ADMAADMA Biologics Enters Into $100 Million Credit Facility Loan Amendment with Perceptive Advisors Increases Size of Facility and Extends Interest-Only Period Enabling ADMA to Reach Profitability Prior to Maturity Demonstra
ADMA Biologics Enters Into $100 Million Credit Facility Loan Amendment with Perceptive Advisors Increases Size of Facility and Extends Interest-Only Period Enabling ADMA to Reach Profitability Prior to Maturity Demonstrates Perceptive's Commitment and Long-Term Positive Outl
Read more →ADMAADMA Biologics Opens Newest ADMA BioCenters Plasma Collection Facility in Maryville, TN
RAMSEY, N.J. and BOCA RATON, Fla. and MARYVILLE, Tenn., Dec. 01, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, toda
Read more →ADMAADMA Biologics to Participate in Jefferies 2020 Virtual London Healthcare Conference
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today an
Read more →ADMAADMA Biologics Reports Third Quarter 2020 Financial Results and Business Highlights Generated Total Revenues of $28.3 Million for the First Nine Months of 2020, Reflecting a 63% Increase Over the Same Prior Year Period S
ADMA Biologics Reports Third Quarter 2020 Financial Results and Business Highlights Generated Total Revenues of $28.3 Million for the First Nine Months of 2020, Reflecting a 63% Increase Over the Same Prior Year Period Successfully Opened Newest ADMA BioCenters Plasma Collec
Read more →ADMAADMA Biologics to Report Third Quarter 2020 Financial Results and Business Highlights on November 5, 2020
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the Compa
Read more →ADMAADMA Biologics Announces Presentation on Respiratory Viral Infections and New Data on S. Pneumoniae at IDWeek 2020
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today an
Read more →ADMAADMA Biologics to Participate in Morgan Stanley Virtual Healthcare Conference
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 09, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today a
Read more →ADMAADMA Biologics Highlights Launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA Assay to Detect SARS-CoV-2 Neutralizing Antibodies in Plasma ImmunoRank Offers a Faster, Simpler, More Cost Effective Way to Identify Hig
ADMA Biologics Highlights Launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA Assay to Detect SARS-CoV-2 Neutralizing Antibodies in Plasma ImmunoRank Offers a Faster, Simpler, More Cost Effective Way to Identify High Titer Convalescent Plasma for Use in Both Treating COVI
Read more →ADMAADMA Biologics to Participate in Upcoming Investor Conferences
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 02, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today a
Read more →ADMAADMA Biologics Reports Business Highlights and Second Quarter 2020 Financial Results Generated Total Revenues of $18.0 Million for the First Half of 2020, Reflecting a 78% Increase Over First Half of 2019 Joined CoVIg-19
ADMA Biologics Reports Business Highlights and Second Quarter 2020 Financial Results Generated Total Revenues of $18.0 Million for the First Half of 2020, Reflecting a 78% Increase Over First Half of 2019 Joined CoVIg-19 Plasma Alliance and Successfully Opened New ADMA BioCe
Read more →ADMAADMA Biologics to Report Business Highlights and Second Quarter 2020 Financial Results on August 5, 2020
RAMSEY, N.J. and BOCA RATON, Fla., July 29, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the Compa
Read more →ADMAADMA Biologics Opens Its Newest ADMA BioCenters Plasma Collection Facility RAMSEY, N.J. and BOCA RATON, Fla. and KNOXVILLE, TN.
ADMA Biologics Opens Its Newest ADMA BioCenters Plasma Collection Facility RAMSEY, N.J. and BOCA RATON, Fla. and KNOXVILLE, TN. - July 6, 2020 - ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, market
Read more →ADMAADMA Biologics Announces Martha J. Demski Elected to Board of Directors
RAMSEY, N.J. and BOCA RATON, Fla., June 23, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the
Read more →ADMAADMA Biologics to Participate in Jefferies Virtual Healthcare Conference RAMSEY, N.J. and
ADMA Biologics to Participate in Jefferies Virtual Healthcare Conference RAMSEY, N.J. and BOCA RATON, Fla., May 27, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufact
Read more →ADMAADMA Biologics Commences Collection of COVID-19 Plasma from Recovered Patients RAMSEY, N.J. and
Commences Collection of COVID-19 Plasma from Recovered Patients RAMSEY, N.J. and BOCA RATON, Fla. - May 21, 2020 - ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA"), today announced it has commenced the collection of convalescent plasma through its wholly-owned subsidiary, ADMA Bi
Read more →ADMAADMA Biologics Provides Corporate Update on Supply Chain Robustness and Recent Accomplishments
RAMSEY, N.J. and BOCA RATON, Fla., May 07, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immuno
Read more →ADMAADMA Biologics Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress Achieved First Quarter 2020 Total Revenues of $10.2 Million, a 189% Increase Over First Quarter 2019 Strengthened Balance
ADMA Biologics Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress Achieved First Quarter 2020 Total Revenues of $10.2 Million, a 189% Increase Over First Quarter 2019 Strengthened Balance Sheet Through Successful Completion of Underwritten Pu
Read more →ADMAADMA Biologics to Report First Quarter 2020 Financial Results on May 6, 2020
RAMSEY, N.J. and BOCA RATON, Fla., April 29, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immu
Read more →ADMAADMA Biologics Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress Achieved Fourth Quarter 2019 Total Revenues of $12.0 Million, a 197% Increase Over Fourth Quarter 2018 Ach
ADMA Biologics Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress Achieved Fourth Quarter 2019 Total Revenues of $12.0 Million, a 197% Increase Over Fourth Quarter 2018 Achieved Full Year 2019 Total Revenues of $29.3 Million, a
Read more →ADMAADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immu
Read more →ADMAADMA Biologics Highlights Expanded Intellectual Property Portfolio for Specialty Plasma Derived Immune Globulins Targeted Against Respiratory Infections
Company Offers Assistance with Coronavirus Global Health Initiatives Company Receives Notification from USPTO Regarding Extension to Its Issued Patents Related and Applied to Composition and Therapeutic Use of Immune Globulin; Extension Expected to Publish in 1H2020 RAMSEY, N.J
Read more →ADMAADMA Biologics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock RAMSEY, NJ and
ADMA Biologics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock RAMSEY, NJ and BOCA RATON, FL, February 24, 2020 -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA"), an end-to-end commer
Read more →ADMAADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV RAMSEY, NJ and
ADMA Biologics Receives BioNJ 2020 Innovator RAMSEY, NJ and BOCA RATON, FL, February 11, 2020 -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for
Read more →ADMAADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the tr
Read more →ADMAADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock RAMSEY, N.J. and BOCA RATON, Fla., Feb. 6 , 2020 (Global Newswire) - ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company") an end-to-e
ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock RAMSEY, N.J. and BOCA RATON, Fla., Feb. 6, 2020 (Global Newswire) - ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company") an end-to-end commercial biopharmaceutical company dedicated to manu
Read more →ADMAADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook Achieved Fourth Quarter 2019 Preliminary Unaudited Total Revenues of $11.9 Million, a 193% Increase Over
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook Achieved Fourth Quarter 2019 Preliminary Unaudited Total Revenues of $11.9 Million, a 193% Increase Over Fourth Quarter 2018 Full Year 2019 Preliminary Unaudite
Read more →ADMAADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions Agreement is Expected to Add $5-10 Million in Annual Revenues for 2020 and 2021, and $10-20 Millio
ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions Agreement is Expected to Add $5-10 Million in Annual Revenues for 2020 and 2021, and $10-20 Million Per Year for 2022 Through 2024 RAMSEY, N.J. and BOCA R
Read more →ADMAADMA Biologics Added to NASDAQ Biotechnology Index RAMSEY, N.J. and
ADMA Biologics Added to NASDAQ Biotechnology RAMSEY, N.J. and BOCA RATON, FL., December 17, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-deriv
Read more →ADMAADMA Biologics to Present at Jefferies 2019 London Healthcare Conference RAMSEY, N.J. and
to Present at Jefferies 2019 London Healthcare Conference RAMSEY, N.J. and BOCA RATON, Fla., November 13, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and de
Read more →ADMAADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress Third Quarter Total Revenues of $7.2 Million, a 71% Increase Year Over Year Commercial Rollouts for Immunoglobulins (IVIG
ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress Third Quarter Total Revenues of $7.2 Million, a 71% Increase Year Over Year Commercial Rollouts for Immunoglobulins (IVIG) Off to an Encouraging Start RAMSEY, N.J. and BOCA RA
Read more →ADMAADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics Association
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 04, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of
Read more →ADMAADMA Biologics Named Company of the Year by BioFlorida RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Named Company of the Year RAMSEY, N.J. and BOCA RATON, FL., - October 22, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived b
Read more →ADMAADMA Biologics Announces First Commercial Sales of ASCENIV RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Announces First Commercial RAMSEY, N.J. and BOCA RATON, FL., - October 21, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived
Read more →ADMAADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM and ASCENIV in the Peer Reviewed Journal Immunotherapy RAMSEY, N.J. and BOCA RATON,
ADMA Biologics Announces Publication Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM and ASCENIV in the Peer Reviewed Journal Immunotherapy RAMSEY, N.J. and BOCA RATON, FL., - October 17, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA
Read more →ADMAADMA Biologics Announces Data Presented at IDWeek 2019 RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Announces Data Presented RAMSEY, N.J. and BOCA RATON, FL., - October 7, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and
Read more →ADMAADMA Biologics Announces Poster Presentation at IDWeek 2019 RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Announces Poster Presentation RAMSEY, N.J. and BOCA RATON, FL., - October 3, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, market
Read more →ADMAADMA Biologics to Present at 2019 Cantor Global Healthcare Conference RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference RAMSEY, N.J. and BOCA RATON, FL., - September 23, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin comp
Read more →ADMAADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM RAMSEY, N.J. and BOCA RATON, FL., - August 22, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immun
Read more →ADMAADMA Biologics Reports Second Quarter and First Half 2019 Financial Results RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results RAMSEY, N.J. and BOCA RATON, FL., - August 8, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin co
Read more →ADMAADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM and Nabi-HB All Aspects of the Biotest Therapy Business Unit ("BTBU") Acquisition Are Successfully Completed RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM and Nabi-HB All Aspects of the Biotest Therapy Business Unit ("BTBU") Acquisition Are Successfully Completed RAMSEY, N.J. and BOCA RATON, FL., - July 8, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA"
Read more →ADMAADMA Biologics to Present at Upcoming Investor Conferences Jefferies 2019 Healthcare Conference Raymond James Life Sciences and MedTech Conference RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics to Present at Upcoming Investor Conferences Jefferies 2019 Healthcare Conference Raymond James Life Sciences and MedTech RAMSEY, N.J. and BOCA RATON, FL., - May 29, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated c
Read more →ADMAADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares RAMSEY, N.J. and
ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares RAMSEY, N.J. and BOCA RATON, FL., May 21, 2019 - ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company") a vertically integrated com
Read more →ADMAADMA Biologics Announces Pricing of Public Offering of Common Stock
RAMSEY, N.J. and BOCA RATON, Fla., May 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-der
Read more →ADMAADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock RAMSEY, N.J. and
ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock RAMSEY, N.J. and BOCA RATON, FL., May 15, 2019 - ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company") a vertically integrated commercial biopharmaceutical and specialty immunoglobulin compa
Read more →ADMAFDA Approves Prior Approval Supplement for BIVIGAM ADMA Announces it will Commence Commercial Sales of BIVIGAM RAMSEY, N.J. and BOCA RATON, FL.
FDA Approves Prior Approval Supplement ADMA Announces it will Commence Commercial RAMSEY, N.J. and BOCA RATON, FL., - May 10, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobuli
Read more →ADMAADMA Biologics Reports First Quarter 2019 Financial Results RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Reports First Quarter 2019 Financial Results RAMSEY, N.J. and BOCA RATON, FL., - May 8, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufact
Read more →ADMAADMA Biologics Elects to Draw-Down $27.5 Million in Capital from Existing Perceptive Advisors Credit Agreement Perceptive Advisors Provides Additional Funding Tranche Commitment of $12.5 Million Available Upon FDA Approv
ADMA Biologics Elects to Draw-Down $27.5 Million in Capital from Existing Perceptive Advisors Credit Agreement Perceptive Advisors Provides Additional Funding Tranche Commitment of $12.5 Million Available Upon FDA Approval of BIVIGAM RAMSEY, N.J. and BOCA RATON, FL., - May 3
Read more →ADMAADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections Fifth Patent Issued to the Company in the U.S. Provides Coverage for Expanding the Company's Hyperimmune IVIG Portfolio Through 2
ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections Fifth Patent Issued to the Company in the U.S. Provides Coverage for Expanding the Company's Hyperimmune IVIG Portfolio Through 2037 RAMSEY, N.J. and BOCA RATON, FL., April 17, 2019 - A
Read more →ADMAADMA Receives Department of Health and Human Services U.S. License RAMSEY, N.J. and BOCA RATON, FL.
ADMA Receives Department of Health and RAMSEY, N.J. and BOCA RATON, FL., - April 2, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and de
Read more →ADMAFDA Approves ASCENIV , a Novel Intravenous Immune Globulin Approved for Use in the Treatment of Primary Humoral Immunodeficiency Disease ("PIDD" or "PI") in Adults and Adolescents (12 to 17 Years of Age) FDA Approval Tri
FDA Approves ASCENIV , a Novel Intravenous Immune Globulin RAMSEY, N.J. and BOCA RATON, FL., - April 1, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufac
Read more →ADMAADMA Biologics Reports Full Year 2018 Financial Results RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Reports Full Year 2018 RAMSEY, N.J. and BOCA RATON, FL., - March 13, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and de
Read more →ADMAADMA Biologics to Present at Upcoming Investor Conferences Raymond James 40 th Annual Institutional Investors Conference Oppenheimer's 29 th Annual Healthcare Conference RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics to Present at Upcoming Investor Conferences Raymond James 40th Annual Institutional Investors Conference Annual Healthcare Conference RAMSEY, N.J. and BOCA RATON, FL., - February 25, 2019 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vert
Read more →ADMAADMA Biologics Enters Into $72.5 Million Loan Facility with Perceptive Advisors Provides Funding to Support Ongoing Activities Including Inventory Ramp, Plant Expansion, Product Launch and Plasma Collection Center Develo
ADMA Biologics Enters Into $72.5 Million Loan Facility with Perceptive Advisors Provides Funding to Support Ongoing Activities Including Inventory Ramp, Plant Expansion, Product Launch and Plasma Collection Center Development RAMSEY, N.J. and BOCA RATON, FL., - February 12, 2
Read more →ADMAADMA Biologics Submits Response and Provides Supplemental Information to FDA for BIVIGAM Complete Response Letter
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-d
Read more →ADMAADMA Biologics, Inc. - Regulatory Update on Bivigam PAS Submissions Call
C O R P O R A T E P A R Jeremy Feffer, Managing Director, LifeSci Advisors, LLC Adam Grossman, President and Chief C O N F E R E N C E C A L L P A R T I C I P A N T S Jason McCarthy, Maxim Group Leland Gershel, Oppenheimer and Edward Marks, H.C. Wainwright Yale Jen, Laid
Read more →ADMAADMA Biologics Provides Regulatory Update on BIVIGAM PAS Submissions FDA Issues Complete Response Letter for PAS Drug Substance, Approves PAS for Drug Product RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Provides Regulatory Update on BIVIGAM PAS Submissions FDA Issues Complete Response Letter for PAS Drug Substance, Approves PAS for Drug Product RAMSEY, N.J. and BOCA RATON, FL., - December 19, 2018 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"
Read more →ADMAADMA Biologics Provides Regulatory Update for BIVIGAM FDA PDUFA Action Anticipated RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Provides Regulatory Update FDA PDUFA Action Anticipated RAMSEY, N.J. and BOCA RATON, FL., - December 19, 2018 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), announces that as of the time of this press release the Company has not received any f
Read more →ADMAADMA Biologics Reports Third Quarter 2018 Financial Results RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Reports Third Quarter 2018 Financial Results RAMSEY, N.J. and BOCA RATON, FL., - November 8, 2018 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical company that develops, manufactures and marke
Read more →ADMAADMA Biologics Receives PDUFA Date for RI-002
Resubmission of Biologics License Application (“BLA”) Reinforces the Company’s Commitment to Commercialize Novel Therapies for Immune Compromised Patients to Address Unmet Medical Needs RAMSEY, N.J. and BOCA RATON, Fla., Oct. 17, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NA
Read more →ADMAADMA Biologics Receives PDUFA Date for RI-002 Resubmission of Biologics License Application ("BLA") Reinforces the Company's Commitment to Commercialize Novel Therapies for Immune Compromised Patients to Address Unmet Me
ADMA Biologics Receives PDUFA Date for Resubmission of Biologics License Application ("BLA") Reinforces the Company's Commitment to Commercialize Novel Therapies for Immune Compromised Patients to Address Unmet Medical Needs RAMSEY, NJ & BOCA RATON, FL- October 17, 2018 - AD
Read more →ADMAADMA Biologics Provides Regulatory Update for BIVIGAM RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Provides Regulatory Update RAMSEY, N.J. and BOCA RATON, FL., - October 11, 2018 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets
Read more →ADMAADMA BioCenters Receives FDA Approval for Third Plasma Collection Center RAMSEY, NJ & MARIETTA, GA
ADMA BioCenters Receives FDA Approval for Third Plasma Collection Center RAMSEY, NJ & MARIETTA, GA - October 3, 2018 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical company that develops, manufactures and m
Read more →ADMAADMA Biologics Resubmits Biologics License Application for RI-002 RAMSEY, NJ &
ADMA Biologics Resubmits Biologics License Application for RI-002 RAMSEY, NJ & BOCA RATON, FL- October 1, 2018 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets
Read more →ADMAADMA Biologics Reports FDA Compliance Status for its Manufacturing Facility has Improved FDA Inspection Database Confirms VAI Status of Boca Raton, FL Facility RI-002's Biologics License Application ("BLA") Resubmission
ADMA Biologics Reports FDA Compliance Status for its Manufacturing Facility has Improved FDA Inspection Database Confirms VAI Status of Boca Raton, FL Facility RI-002's Biologics License Application ("BLA") Resubmission Targeted for RAMSEY, N.J. and BOCA RATON, FL., - Septem
Read more →ADMAADMA Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 27, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Pri
Read more →ADMAADMA Biologics to Present at the 20 th Annual Rodman & Renshaw Global Investment Conference RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference RAMSEY, N.J. and BOCA RATON, FL., - August 27, 2018 - ADMA Biologics, Inc. (NASDAQ: ADMA) (the "Company"), a vertically integrated commercial biopharmaceutical company that develops, ma
Read more →ADMAADMA Biologics Reports Second Quarter 2018 Financial Results Key Regulatory & Manufacturing Milestones Achieved RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Reports Second Quarter 2018 Financial Results Key Regulatory & Manufacturing Milestones RAMSEY, N.J. and BOCA RATON, FL., - August 10, 2018 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company") today announced its financial results for the quarter en
Read more →ADMAADMA Biologics Reports Successful Close-Out of its April 2018 FDA Compliance Inspection FDA Establishment Inspection Report ("EIR") Received RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Reports Successful Close-Out of its April 2018 FDA Compliance Inspection FDA Establishment Inspection Report ("EIR") RAMSEY, N.J. and BOCA RATON, FL., - July 26, 2018 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated comm
Read more →ADMAADMA Biologics Receives PDUFA Date for BIVIGAM Regulatory Submission Prior Approval Supplement ("PAS") to Amend the Biologics License Application ("BLA") for BIVIGAM is Supported by Data and Documentation Prepared Using
ADMA Biologics Receives PDUFA Date for BIVIGAM Regulatory Submission Prior Approval Supplement ("PAS") to Amend the Biologics License Application ("BLA") for BIVIGAM is Supported by Data and Documentation Prepared Using ADMA's Optimized IVIG Manufacturing Process Demonstratin
Read more →ADMAADMA Biologics Added to the Russell 3000 and Russell 2000 Indexes RAMSEY, N.J. and
ADMA Biologics Added to the Russell 3000 and Russell 2000 Indexes RAMSEY, N.J. and BOCA RATON, FL., June 25, 2018 - ADMA Biologics, Inc. (NASDAQ: ADMA), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based
Read more →ADMAADMA Biologics Announces Closing of $40M Public Offering RAMSEY, N.J. and
ADMA Biologics Announces Closing of $40M Public Offering RAMSEY, N.J. and BOCA RATON, FL., June 12, 2018 - ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company") announced today the closing of its previously announced underwritten public offering of 8,368,200 shares of
Read more →ADMAADMA Biologics Announces Proposed Public Offering of Common Stock RAMSEY, N.J. and
ADMA Biologics Announces Proposed Public Offering of Common Stock RAMSEY, N.J. and BOCA RATON, FL., June 7, 2018 - ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company") announced today that it has commenced an underwritten public offering of its common stock. The Comp
Read more →ADMAADMA Biologics Granted U.S. Patent for Treating Respiratory Infections Fourth Patent Issued to the Company in the U.S. Provides Coverage for RI-002 Through 2035 RAMSEY, N.J. and
ADMA Biologics Granted U.S. Patent for Treating Respiratory Infections Fourth Patent Issued to the Company in the U.S. Provides Coverage for RI-002 Through 2035 RAMSEY, N.J. and BOCA RATON, FL., May 16, 2018 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company") tod
Read more →ADMAADMA Biologics Retires Approximately 8.6 Million Shares Previously Issued to Biotest Capital Structure Improved as Total Outstanding Common Stock Reduced By Approximately 19% RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Retires Approximately 8.6 Million Shares Previously Issued to Biotest Capital Structure Improved as Total Outstanding Common Stock Reduced By Approximately 19% RAMSEY, N.J. and BOCA RATON, FL., - May 14, 2018 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or th
Read more →ADMAADMA Biologics Reports First Quarter 2018 Financial Results
RAMSEY, N.J. and BOCA RATON, Fla., May 14, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), today announced its financial results for the quarter ended March 31, 2018 and provided an update on its operations and corporate objectives. “During
Read more →ADMAADMA Biologics Announces the Release of its First Commercial Batch of Nabi-HB Manufactured Under its Ownership Operational Leadership Team Executes on Production and Commercialization of the Company's Immune Globulin Pro
ADMA Biologics Announces the Release of its First Commercial Batch of Nabi-HB Manufactured Under its Ownership Operational Leadership Team Executes on Production and Commercialization of the Company's Immune Globulin Product for the Treatment of Hepatitis B Infection RAMSEY,
Read more →ADMAADMA Biologics Reports Full Year 2017 Financial Results RAMSEY, N.J. and BOCA RATON, FL.
ADMA Biologics Reports Full Year 2017 RAMSEY, N.J. and BOCA RATON, FL., - March 5, 2018 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and dev
Read more →ADMAADMA Biologics to Present at Raymond James’ 39th Annual Institutional Investors Conference
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatme
Read more →ADMAADMA Files Biologics License Application For Its Third Plasma Collection Center ADMA BioCenters' Newest Facility Commences Operations to Further Supplement Supply of Internally-Sourced Donor Plasma for Commercial Product
ADMA Files Biologics License Application For Its Third Plasma Collection Center ADMA BioCenters' Newest Facility Commences Operations to Further Supplement Supply of Internally-Sourced Donor Plasma for Commercial Products and Pipeline of Hyperimmune RAMSEY, NJ & MARIETTA, GA-
Read more →ADMAADMA Biologics Further Enhances Intellectual Property Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Compositions RAMSEY, N.J. and
ADMA Biologics Further Enhances Intellectual Property Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Compositions RAMSEY, N.J. and BOCA RATON, FL., November 15, 2017 - ADMA Biologics, Inc. (NASDAQ: ADMA) is a vertically integrated biopharmaceutical and specia
Read more →ADMAADMA Biologics Announces Closing of $42M Follow-On Offering RAMSEY, N.J. &
ADMA Biologics Announces Closing of $42M RAMSEY, N.J. & BOCA RATON, FL - November 13, 2017 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and
Read more →ADMAADMA Biologics Announces Pricing of Follow-On Offering RAMSEY, N.J.
ADMA Biologics Announces Pricing of Follow-On RAMSEY, N.J. - November 9, 2017 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets spec
Read more →ADMAADMA Biologics Provides Corporate Update and Reports Third Quarter 2017 Financial Results RAMSEY, N.J.
ADMA Biologics Provides Corporate Update and Reports Third Quarter 2017 Financial Results RAMSEY, N.J. - November 3, 2017 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company
Read more →ADMAMarathon Asset Management and ADMA Biologics Complete $30 Million Debt Refinancing New Debt Facility Provides Cash Runway Extension and an Option to Borrow Additional $10 Million Interest Only Provision for 36 Months RAM
Marathon Asset Management and ADMA Biologics Complete $30 Million Debt Refinancing New Debt Facility Provides Cash Runway Extension and an Option to Borrow Additional $10 Million Interest Only Provision for 36 Months RAMSEY, N.J. - October 11, 2017 - ADMA Biologics, Inc. (N
Read more →ADMAADMA Biologics to Present at Upcoming Investor Conferences
RAMSEY, N.J., Aug. 23, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets specialty plasma-based biologics for the treatment
Read more →ADMAADMA Biologics Provides Corporate Update and Reports Second Quarter 2017 Financial Results RAMSEY, N.J.
ADMA Biologics Provides Corporate Update and Reports Second Quarter 2017 Financial Results RAMSEY, N.J. - August 11, 2017 - ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated biopharmaceutical and specialty immunoglobulin company that devel
Read more →ADMAADMA Biologics Strengthens Patent Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Methods RAMSEY, N.J. and
ADMA Biologics Strengthens Patent Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Methods RAMSEY, N.J. and BOCA RATON, FL., July 31, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) is a vertically integrated biopharmaceutical and specialty immunog
Read more →ADMAADMA Biologics Provides Corporate Timeline and Activities Update to Stockholders RAMSEY, N.J. and
ADMA Biologics Provides Corporate Timeline and Activities Update to Stockholders RAMSEY, N.J. and BOCA RATON, FL. - June 27, 2017 - ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures and commercializes specialty plasma-based
Read more →ADMAADMA Biologics Completes Acquisition of Biotest's Therapy Business Unit Assets Transaction Creates Vertically Integrated Commercial Plasma Products Company Combined Entity has Multi-Faceted Revenue Generation Platform wi
ADMA Biologics Completes Acquisition of Biotest's Therapy Business Unit Assets Transaction Creates Vertically Integrated Commercial Plasma Products Company Combined Entity has Multi-Faceted Revenue Generation Platform with FDA Licensed Products, Source Plasma Collection and
Read more →ADMAADMA Biologics Stockholders Vote to Approve Acquisition of Certain Assets from Biotest Pharmaceuticals Corporation RAMSEY, N.J.
ADMA Biologics Stockholders Vote to Approve Acquisition of Certain Assets from Biotest Pharmaceuticals Corporation RAMSEY, N.J. - May 30, 2017 - ADMA Biologics, Inc. (NASDAQ: ADMA) announced today that its stockholders voted to approve ADMA's previously announced acquisition o
Read more →ADMAADMA Biologics to Present at Jefferies 2017 Healthcare Conference RAMSEY, N.J.
ADMA Biologics to Present at Jefferies 2017 Healthcare Conference RAMSEY, N.J. - May 25, 2017 - ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the propo
Read more →ADMAADMA Biologics Provides Corporate Update and Reports First Quarter 2017 Financial Results RAMSEY, N.J.
ADMA Biologics Provides Corporate Update and Reports First Quarter 2017 Financial Results RAMSEY, N.J. - May 12, 2017 - ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based
Read more →ADMAUnassociated Document ADMA Biologics Reports Year End 2016 Financial Results Accomplishments and Upcoming Milestones RAMSEY, N.J.
ADMA Biologics Reports Year End 2016 Financial Results Accomplishments and Upcoming Milestones RAMSEY, N.J. - February 24, 2017 - ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plas
Read more →ADMAADMA Biologics Reports Year End 2016 Financial Results, Accomplishments and Upcoming Milestones
RAMSEY, N.J., Feb. 24, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention o
Read more →ADMAADMA Biologics to Acquire Certain Assets from Biotest Pharmaceuticals Corporation and Become a Vertically Integrated Commercial Plasma Products Company
Ownership and control of U.S. based Immune Globulin manufacturing facility FDA licensed products portfolio with immediate and on-going commercial sales $40M in Equity/Debt Financing from Biotest AG; ADMA’s cash runway presently expected to be extended to 2H 2018 RAMSEY, N.J.,
Read more →ADMAUnassociated Document Filed by ADMA Biologics, Inc. pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: ADMA Biologics, Inc. Commission File No.: 001-36728 ADMA Biologics to Acq
Filed by ADMA Biologics, Inc. pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: ADMA Biologics, Inc. Commission File No.: 001-36728 ADMA Biologics to Acquire Certain Assets from Biotest Pharmaceuticals Corporation and Become a Ver
Read more →ADMAADMA Biologics Reports Third Quarter 2016 Results RAMSEY, N.J.
ADMA Biologics Reports Third Quarter 2016 Results RAMSEY, N.J. - November 10, 2016 - ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment
Read more →ADMAADMA Biologics Reports Third Quarter 2016 Results
RAMSEY, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention o
Read more →ADMAUnassociated Document
Unassociated Document
Read more →ADMAADMA Biologics Reports Second Quarter 2016 Results RAMSEY, N.J.
ADMA Biologics Reports Second Quarter 2016 Results RAMSEY, N.J. - August 12, 2016 - ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment o
Read more →ADMAADMA Biologics Receives Complete Response Letter from FDA for Pending Biologics License Application RAMSEY, N.J.
ADMA Biologics Receives Complete Response Letter from FDA for Pending Biologics License Application RAMSEY, N.J. July 29, 2016 - ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-
Read more →ADMAADMA Biologics to Present at the 2016 JMP Securities Life Sciences Conference
RAMSEY, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, a
Read more →ADMAADMA Biologics Reports First Quarter 2016 Results Company Announces Recent Accomplishments and Upcoming Milestones RAMSEY, N.J.
ADMA Biologics Reports First Quarter 2016 Results Company Announces Recent Accomplishments and Upcoming Milestones RAMSEY, N.J. - May 13, 2016 - ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize
Read more →ADMAADMA Biologics Further Enhances Cash Position by Securing $4.0 Million in Additional Capital Through Amended Loan and Security Agreement with Oxford Finance
RAMSEY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, tod
Read more →ADMAADMA Biologics Reports First Quarter 2016 Results
RAMSEY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, to
Read more →ADMAADMA Biologics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
RAMSEY, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, an
Read more →ADMAUnassociated Document ADMA Biologics Announces Pricing of Public Offering of Common Stock RAMSEY, N.J.
ADMA Biologics Announces Pricing of Public Offering of Common Stock RAMSEY, N.J., April 28, 2016 - ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treat
Read more →ADMAUnassociated Document ADMA Biologics Announces Proposed Public Offering of Common Stock RAMSEY, N.J.
ADMA Biologics Announces Proposed Public Offering of Common Stock RAMSEY, N.J., April 27, 2016 - ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatme
Read more →ADMAADMA Biologics Announces Data on RI-002 to be Presented at the Clinical Immunology Society 2016 Annual Meeting
RAMSEY, N.J., April 12, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases,
Read more →ADMAADMA Biologics Reports Year End 2015 Financial Results, Accomplishments and Upcoming Milestones RAMSEY, N.J.
ADMA Biologics Reports Year End 2015 Financial Results, Accomplishments and Upcoming Milestones RAMSEY, N.J. - March 23, 2016 - ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-
Read more →ADMAADMA Biologics Announces Data Presented at 2016 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI)
RAMSEY, N.J., March 07, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases,
Read more →ADMAADMA Biologics to Present at Cowen and Company 36th Annual Health Care Conference
RAMSEY, N.J., March 01, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases,
Read more →ADMAADMA Biologics Recognized as One of New Jersey’s “Best Places to Work 2016”
RAMSEY, N.J., Feb. 24, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, an
Read more →ADMAADMA Biologics Expands Commercial Operations Team in Preparation for Commercial Launch of RI-002 in Second Half of 2016
RAMSEY, N.J., Dec. 09, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), announced today the expansion of its commercial operations team, appointing Alan Erck as the Company’s Vice President, Sales and National Accounts. ADMA Biologics is a late-stage biopharmaceutical
Read more →ADMAADMA Biologics to Present at the Oppenheimer 26th Annual Healthcare Conference
RAMSEY, N.J., Dec. 03, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, to
Read more →ADMAADMA Biologics Reports Third Quarter 2015 Results
RAMSEY, N.J., Nov. 10, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, an
Read more →ADMAADMA Biologics Reports Third Quarter 2015 Results RAMSEY, N.J.
ADMA Biologics Reports Third Quarter 2015 Results RAMSEY, N.J., November 10, 2015 - ADMA Biologics, Inc. (Nasdaq: ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevent
Read more →ADMAADMA Biologics Announces Data to be Presented at the International Primary Immunodeficiencies Congress in Budapest Hungary
RAMSEY, N.J., Nov. 03, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, t
Read more →ADMAADMA Biologics Receives Milestone Payment From Biotest AG for RI-002 BLA Submission to FDA
RAMSEY, N.J., Sept. 30, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases,
Read more →ADMAADMA Biologics Recognized as One of the 50 Fastest Growing Companies in New Jersey
RAMSEY, N.J., Sept. 28, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases,
Read more →ADMAADMA Biologics to Present at the Ladenburg Thalmann 2015 Healthcare Conference
RAMSEY, N.J., Sept. 22, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases,
Read more →ADMAADMA Biologics Receives FDA Approval for Second Plasma Collection Center
RAMSEY, N.J., Sept. 17, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics, announced that the Company's second plasma center, located at 30
Read more →ADMAADMA Biologics to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
RAMSEY, N.J., Sept. 2, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, a
Read more →ADMAADMA Biologics Receives Patent Issuance Pertaining to the Treatment of Immunodeficiency
RAMSEY, N.J., Aug. 31, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company, announced that the U.S. Patent and Trademark Office (USPTO) has issued United States Patent 9,107,906. The patent titled, 'Compositions And Methods For The
Read more →ADMAADMA Biologics Reports Second Quarter 2015 Results Provides Corporate Update and Anticipated Upcoming Milestones RAMSEY, N.J.
ADMA Biologics Reports Second Quarter 2015 Results Provides Corporate Update and Anticipated Upcoming Milestones RAMSEY, N.J., August 11, 2015 - ADMA Biologics, Inc. (Nasdaq: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize
Read more →ADMAADMA Biologics Announces Submission of RI-002 Biologics License Application (BLA) to FDA
RAMSEY, N.J., July 31, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the primary immunodeficiency (PI) population and the treatment
Read more →ADMAADMA Biologics Announces Recent Commercialization Focused Appointments
Senior Vice President of Commercialization & Strategy Vice President of Medical Affairs Senior Director of Supply Chain Operations RAMSEY, N.J., July 6, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactu
Read more →ADMAADMA Biologics Receives Notice of Allowance for U.S. Patent Pertaining to Its Lead Product Candidate RI-002
RAMSEY, N.J., June 30, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company, announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application 14/592,721 entitled Compositions an
Read more →ADMAADMA Biologics Joins Russell Microcap(R) Index
RAMSEY, N.J., June 29, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company developing specialty plasma-based biologics for the primary immunodeficiency (PI) population and the treatment and prevention of certain infectious diseases,
Read more →ADMACHARTER 2 e613828_ex99-1.htm Unassociated Document
CHARTER 2 e613828_ex99-1.htm Unassociated Document
Read more →ADMAADMA Biologics Secures Up to $21 Million Loan Commitment From Oxford Finance RAMSEY, N.J.
ADMA Biologics Secures Up to $21 Million Loan Commitment From Oxford Finance RAMSEY, N.J., June 22, 2015 - ADMA Biologics, Inc. (Nasdaq: ADMA), a late-stage biopharmaceutical company developing specialty plasma-based biologics for the treatment and prevention of certain infectio
Read more →ADMAADMA Biologics to Present at the 2015 JMP Securities Life Sciences Conference
RAMSEY, N.J., June 16, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announce
Read more →ADMAADMA Biologics & Jeffrey Modell Foundation Initiate Strategic Patient Advocacy Alliance
RAMSEY, N.J., June 11, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company developing specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it has initiated a collaboration
Read more →ADMAADMA Biologics to Present at the 2015 Marcum MicroCap Conference
RAMSEY, N.J., May 22, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced
Read more →ADMAADMA Biologics Reports First Quarter 2015 Results Provides Corporate Update and Anticipated Upcoming Milestones RAMSEY, N.J.
ADMA Biologics Reports First Quarter 2015 Results Provides Corporate Update and Anticipated Upcoming Milestones RAMSEY, N.J., May 12, 2015 - ADMA Biologics, Inc. (Nasdaq: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty
Read more →ADMAADMA Biologics Reports First Quarter 2015 Results
RAMSEY, N.J., May 12, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced
Read more →ADMAADMA Biologics Announces Data to be Presented at the Clinical Immunology Society 2015 Annual Meeting
RAMSEY, N.J., April 7, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today an
Read more →ADMAADMA Biologics Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
RAMSEY, N.J., March 18, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announc
Read more →ADMAADMA Biologics Announces Pricing of Public Offering of Common Stock RAMSEY, N.J.
ADMA Biologics Announces Pricing of Public Offering of Common Stock RAMSEY, N.J., March 13, 2015 - ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment an
Read more →ADMAADMA Biologics Reports Year End 2014 Results and Upcoming Milestones RAMSEY, N.J.
ADMA Biologics Reports Year End 2014 Results and Upcoming Milestones RAMSEY, N.J., March 9, 2015 - ADMA Biologics, Inc. (Nasdaq: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment an
Read more →ADMAADMA Biologics Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference
RAMSEY, N.J., Feb. 23, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announce
Read more →ADMAADMA Biologics to Present at Cowen and Company 35th Annual Health Care Conference
RAMSEY, N.J., Feb. 20, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today an
Read more →ADMAADMA Biologics Announces Data to be Presented at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI)
RAMSEY, N.J., Feb. 17, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today an
Read more →ADMAADMA Biologics Receives $5M Tranche From Hercules Technology Growth Capital
RAMSEY, N.J., Dec. 15, 2014 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today an
Read more →ADMAADMA Biologics Announces Positive Top-Line Phase III Data for Primary Immune Deficiency Disease (PIDD) Patients
RAMSEY, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today ann
Read more →ADMAADMA Biologics to Present at the Oppenheimer 25th Annual Healthcare Conference
RAMSEY, N.J., Dec. 2, 2014 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today ann
Read more →ADMAADMA Biologics, Inc. (Nasdaq:ADMA) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Nov. 25, 2014 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Adam Gros
Read more →ADMAADMA Biologics Opens Plasma Collection Center in Marietta, Georgia
RAMSEY, N.J. and MARIETTA, Ga., Nov. 18, 2014 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), today announced the opening of its second plasma collection facility in Marietta, Georgia. "Demand for plasma donation is thriving in the metro Atlanta area and our expansion in
Read more →ADMAADMA Biologics Reports Third Quarter 2014 Financial and Operational Results RAMSEY, N.J.
ADMA Biologics Reports Third Quarter 2014 Financial and Operational Results RAMSEY, N.J. - November 10, 2014 - ADMA Biologics, Inc. (ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatme
Read more →ADMAADMA Biologics to Present at the 9th International Respiratory Syncytial Virus (RSV) Symposium
RAMSEY, N.J., Nov. 10, 2014 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), announced today that it will be presenting data describing the composition and efficacy in an animal model of its polyclonal IVIG product, RI-002, at the 9th International Respiratory Syncytial Vi
Read more →ADMAADMA Biologics Approved for Trading on NASDAQ
RAMSEY, N.J., Nov. 5, 2014 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today anno
Read more →ADMAUnassociated Document ADMA Biologics Reports Second Quarter 2014 Financial and Operational Results RAMSEY, N.J.
ADMA Biologics Reports Second Quarter 2014 Financial and Operational Results RAMSEY, N.J. - August 11, 2014 - ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the t
Read more →ADMAADMA Biologics Reports First Quarter 2014 Financial and Operational Results RAMSEY, N.J.
ADMA Biologics Reports First Quarter 2014 Financial and Operational Results RAMSEY, N.J. - May 12, 2014 - ADMA Biologics, Inc. (OTCQB: ADMA), a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treat
Read more →ADMAADMA Biologics Reports Year End 2013 Results Ramsey, N.J.
ADMA Biologics Reports Year End 2013 Results Ramsey, N.J., March 28, 2014 - ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain
Read more →ADMAADMA Biologics Secures Up To $15 Million Loan Commitment From Hercules Technology Growth Capital Ramsey, N.J.
ADMA Biologics Secures Up To $15 Million Loan Commitment From Hercules Technology Growth Capital Ramsey, N.J., February 27, 2014 - ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-base
Read more →ADMAADMA Biologics Expands Plasma Collection Operations of ADMA BioCenters Ramsey, N.J., Norcross, G.A., Marietta, G.A.
ADMA Biologics Expands Plasma Collection Operations of ADMA BioCenters Ramsey, N.J., Norcross, G.A., Marietta, G.A., February 3, 2014 - ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma
Read more →ADMAUnassociated Document ADMA Biologics Reports Third Quarter 2013 Financial and Operational Results RAMSEY, N.J.
ADMA Biologics Reports Third Quarter 2013 Financial and Operational Results RAMSEY, N.J., November 12, 2013 - ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the tre
Read more →ADMAUnassociated Document ADMA Biologics, Inc. Announces Pricing of Initial Public Offering Ramsey, N.J.
ADMA Biologics, Inc. Announces Pricing of Initial Public Offering Ramsey, N.J., October 17, 2013 - ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and
Read more →ADMAUnassociated Document ADMA Biologics Reports Second Quarter 2013 Financial and Operational Results RAMSEY, N.J.
ADMA Biologics Reports Second Quarter 2013 Financial and Operational Results RAMSEY, N.J., August 12, 2013 - ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention
Read more →ADMAUnassociated Document ADMA Biologics Reports First Quarter 2013 Financial and Operational Results RAMSEY, N.J.
ADMA Biologics Reports First Quarter 2013 Financial and Operational Results RAMSEY, N.J., May 14, 2013 - ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of
Read more →ADMAUnassociated Document ADMA Biologics Commences Pivotal Phase III Clinical Study of RI-002 in PIDD Patients HACKENSACK, N.J.
ADMA Biologics Commences Pivotal Phase III Clinical Study of RI-002 in PIDD Patients HACKENSACK, N.J., March 7, 2013 - ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and
Read more →ADMAUnassociated Document ADMA Biologics Reports 2012 Year End Financial and Operational Results HACKENSACK, N.J.
ADMA Biologics Reports 2012 Year End Financial and Operational Results HACKENSACK, N.J., March 6, 2013 - ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of
Read more →ADMAUnassociated Document ADMA Biologics Reports 2012 Third Quarter Results HACKENSACK, N.J.
ADMA Biologics Reports 2012 Third Quarter Results HACKENSACK, N.J., November 13, 2012 - ADMA Biologics, Inc. (ADMA), a late-stage biotechnology company focused on the development and commercialization of human plasma and plasma-derived therapeutics, today reported financial resu
Read more →ADMAUnassociated Document ADMA Biologics Reports 2012 Second Quarter Results HACKENSACK, N.J.
ADMA Biologics Reports 2012 Second Quarter Results HACKENSACK, N.J., August 14, 2012 - ADMA Biologics, Inc. (ADMA), a late-stage biotechnology company focused on the development and commercialization of human plasma and plasma-derived therapeutics, today reported financial resul
Read more →ADMAADMA BIOLOGICS, INC. CONSOLIDATED FINANCIAL STATEMENTS Unassociated Document ADMA Biologics, Inc. and Subsidiary Index Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets
ADMA Biologics, Inc. and Subsidiary Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets December 31, 2011 and 2010 F-3 Consolidated Statements of Operations Years Ended December 31, 2011 and 2010 F-4 Consolidated Statements of Changes in Sto
Read more →ADMAUnassociated Document ADMA Biologics Appoints Brian Lenz as Chief Financial Officer HACKENSACK, N.J.
ADMA Biologics Appoints Brian Lenz as Chief Financial Officer HACKENSACK, N.J., May 3, 2012. ADMA Biologics, Inc. ("ADMA"), a clinical stage biotechnology company focused on the development and commercialization of human plasma and plasma-derived therapeutics, today announced th
Read more →ADMAUnassociated Document ADMA Biologics, Inc. and Subsidiary Index Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets
ADMA Biologics, Inc. and Subsidiary Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets December 31, 2011 and 2010 F-3 Consolidated Statements of Operations Years Ended December 31, 2011 and 2010 F-4 Consolidated Statements of Changes in Sto
Read more →ADMAADMA BIOLOGICS, INC. FINANCIAL STATEMENTS Unassociated Document ADMA Biologics, Inc. and Subsidiary Index Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets
ADMA Biologics, Inc. and Subsidiary Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets December 31, 2011 and 2010 F-3 Consolidated Statements of Operations Years Ended December 31, 2011 and 2010 F-4 Consolidated Statements of Changes in Sto
Read more →ADMAADMA Biologics, Inc. and Subsidiary (A Development Stage Enterprise) Index Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets
ADMA Biologics, Inc. and Subsidiary (A Development Stage Enterprise) Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets December 31, 2010 and 2009 F-3 Consolidated Statements of Operations Years Ended December 31, 2010 and 2009 and the
Read more →Competitive Position
How ADMA ranks across every disease it competes inCompetitive Position is a premium feature
See how ADMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial